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ABSTRACT
The largest part of tau secreted from AD nerve terminals and released in cerebral 
spinal fluid (CSF) is C-terminally truncated, soluble and unaggregated supporting 
potential extracellular role(s) of NH2-derived fragments of protein on synaptic 
dysfunction underlying neurodegenerative tauopathies, including Alzheimer’s disease 
(AD). Here we show that sub-toxic doses of extracellular-applied human NH2tau 26-44 
(aka NH2htau) -which is the minimal active moiety of neurotoxic 20-22kDa peptide 
accumulating in vivo at AD synapses and secreted into parenchyma- acutely provokes 
presynaptic deficit in K+-evoked glutamate release on hippocampal synaptosomes 
along with alteration in local Ca2+ dynamics. Neuritic dystrophy, microtubules 
breakdown, deregulation in presynaptic proteins and loss of mitochondria located at 
nerve endings are detected in hippocampal cultures only after prolonged exposure 
to NH2htau. The specificity of these biological effects is supported by the lack of 
any significant change, either on neuronal activity or on cellular integrity, shown 
by administration of its reverse sequence counterpart which behaves as an inactive 
control, likely due to a poor conformational flexibility which makes it unable to 
dynamically perturb biomembrane-like environments. Our results demonstrate that 
one of the AD-relevant, soluble and secreted N-terminally truncated tau forms can 
early contribute to pathology outside of neurons causing alterations in synaptic 
activity at presynaptic level, independently of overt neurodegeneration.
INTRODUCTION
Recently in vitro and in vivo data suggest a crucial 
role of extracellular tau in the initiation/progression 
of AD [1, 2, 3]. Accumulating evidence shows that the 
clearance of extracellular pathological tau forms, which 
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represents the rationale for the promising results of the 
ongoing tau-based immunotherapy, is an actual AD 
therapeutic alternative to the not-encouraging Aβ-based 
pharmacological and immunological approaches [4, 5]. 
Although full length tau is found in cerebral spinal fluid 
(CSF) from both normal humans [6] and rodents [7, 
8], a heterogeneous population of fragments of protein 
-including the NH2terminal and/or proline-rich domain- is 
for the most part detected in CSF from AD subjects [9, 
10, 11, 12] and in conditioned media from AD patient-
derived induced pluripotent stem cells (iPSC) cortical 
neurons [13]. Interestingly, the largest part of tau secreted 
from different in vitro neuronal models has been recently 
confirmed to be actually C-terminally truncated, soluble, 
unaggregated and released both by vital and dead neurons 
in a way independent of cell damage [14]. Pathological 
hyperphosphorylation and caspase-3 cleavage of tau 
(Asp421) taking place in diseased subjects promote its 
aggregation and also favor the in vitro secretion [15]. 
Besides, the N-terminal projection domain of human 
tau -which interacts with the plasma membrane [16] 
and mediates neurotoxicity mainly at synapses [17]- 
is required for its secretion to the extracellular space 
in in situ tauopathy model [18]. Exosomes-associated 
NH2derived tau fragments are also detected in CSF from 
AD patients and a different pattern of NH2-tau fragments 
in CSF may reflect disease-specific neurodegenerative 
processes [19]. Accordingly, passive immunization with 
different tau antibodies directed against the extreme 
and mid-region in N-terminal end of protein turns out 
to be the most beneficial in reducing pathological tau 
hyperphosphorylation and in improving cognition of 
aged (16-months-old) 3XTg AD mice [20], thus fostering 
the targeting of these selective epitopes as an actual 
opportunity for the cure of AD and other tauopathies. 
Relevantly, a comprehensive mass spectrometry (MS)-
based screening carried out on CSF samples from patients 
affected from AD and other tauopathies has confirmed that 
the first NH2 26-44 aminoacids of human tau are epitopes 
potentially targetable for promising immunotherapeutic 
interventions, being largely represented into proteomic 
profile of diseased secreted proteins [21]. However, the 
identification of the molecular nature of extracellular 
noxious tau species is of central importance for 
developing an effective tau-based immunotherapy and, 
in this framework, the biological effects of AD-relevant 
NH2-truncated human tau forms outside of neurons still 
remain to be determined. In addition, although a potential 
extracellular physiopathological role of full length tau 
has been highlighted, consistent with the recent findings 
that secreted tau is per se toxic on synaptic function 
[22, 23], no study has yet investigated whether one of 
the biologically relevant NH2-truncated forms of protein 
-which are largely detected in diseased CSF and released 
in vivo from AD nerve endings [9, 10, 11]- could affect the 
neurotransmission at the pre-synaptic level. 
To this point, we previously reported that higher 
levels of the 20-22kDa NH2-truncated form of human 
tau - a neurotoxic fragment of the full length protein 
(htau40) mapping between 26 and 230 aminoacids of 
the longest human tau isoform- are largely detectable in 
presynaptic terminals [24, 25, 26] as well in peripheral 
CSFs from living patients affected by AD and not-
AD human neurodegenerative diseases associated to 
dementias [27]. Importantly, following potassium-
induced depolarization, this specific C-terminal truncated 
peptide is preferentially released from AD presynaptic 
nerve endings in comparison with age-matched healthy 
controls [28], thus providing a rationale for investigating 
its potential action outside of neurons. Therefore, given 
the physiopathological role of extracellular tau in the 
regulation of inter-neuronal signaling at synapses [29, 30, 
31, 32] and the prevailing presence of N-terminal/middle 
region-containing truncated forms of protein ranging from 
20-25kDa in AD-derived biological fluids [9, 10, 11, 13], 
we attempted to elucidate the biological effects induced 
by short- and long-term exposure of hippocampal isolated 
synaptosomes and mature primary neurons to subtoxic 
doses of extracellular human NH2htau  26-44 fragment, 
which is the minimal biologically active moiety of longer 
secreted 20-22kDa parental peptide [25, 33, 34]. 
RESULTS
NH2htau 26-44 (aka NH2htau) is highly flexible 
and mainly monomeric in solution
Although tau is an intrinsically disordered protein 
characterized by dynamic ensemble of interconverting 
conformations, recent detailed NMR spectroscopy 
analysis carried out on the full-length longest human 
tau 1-441isoform (htau40) has revealed that the first 
N-terminal 50 residues of protein favor a compact 
conformation displaying an intrinsic propensity to local 
secondary structure(s), as demonstrated by the presence 
of strong contacts within the residue stretch 1-20 and 
from this region to residues 30-50 [35]. In addition, the 
N-terminal residues Leu-Thr transiently form α-helical 
structure promoting a long-range intramolecular 
interactions [36, 37]. In view of these considerations, we 
set about investigating the conformational changes that 
chemically-synthesized (purity up to 99%) human NH2 
26-44 (aka NH2htau) and its reverse control sequence 
(aka reverse) undergo in aqueous solution by circular 
dichroism (CD) spectroscopy, which allows to estimate 
the secondary structural composition of proteins in 
different experimental environments. As shown in 
Figure 1A, NH2htau displayed within the wide range of 
explored pH (pH 4-11) a spectrum typical for an unfolded 
peptide characterized by a strong negative ellipticity 
Oncotarget3www.impactjournals.com/oncotarget
below 200nm which is suggestive of a random coil 
unfolded conformation. No evident sign of structured 
peptide chains was observed in CD spectra recorded in 
experimental conditions similar to those occurring near 
the lipid bilayers (i.e.membrane-mimicking media) such 
as in presence of increasing detergent SDS concentrations 
(Figure 1B) or anionic-zwitterionic phospholipid large 
unilamellar vesicles (LUV) composed by POPC/POPS in 
Figure 1: NH2htau 26-44 (i.e.NH2htau) shows an intrinsically disordered structure and is mainly monomeric in water 
environment. A.-B.-C.-D. CD spectra of NH2htau26-44 (10µM ) at different pH(A), at different concentrations of SDS(B), in presence of 
large unilamellar vesicles (LUV) composed by POPC/POPS 100 µM in a 7/3 ratio at pH7.4 at increasing temperatures (C) and at different 
percentage of TFE(D) are shown. Notice that NH2htau shows in aqueous solution a negative peak typical for an unfolded protein with a 
minimum at 200nm, indicating the general absence of local major conformational changes. E. Kinetics of fiber formation was measured by 
ThT binding assay and ThT fluorescence of Aβ1-40 20 µM (black curve), NH2htau 20 µM in the absence (red curve) and presence of lipid 
LUV TLBE 200 µM (green curve), reverse control peptide (i.e reverse) 20 µM in the absence (blue curve) and presence of lipid LUV TLBE 
200 µM (cyan curve) are reported. All samples were prepared in 10 mM phosphate buffer, pH 7.4, 100 mM NaCl. Time traces reported are 
the average of three experiments. Kinetic curves for Aβ1-40 are classically sigmoidal-shaped indicating an ongoing aggregation growth 
process while no noticeable differences in ThT emission intensity over time are contextually detected for NH2htau and reverse peptides both 
in solution and in presence of lipid membrane mimetics. F.-G. NH2htau and its reverse sequence were dissolved as described in material 
and methods and 150pmol of both peptides were analyzed on 15% SDS-PAGE in reducing conditions. After reversible Sypro Ruby protein 
staining of gel(F), Western blotting analysis was performed by probing with specific 12A12 monoclonal antibody directed against the 
extreme N-terminal 26-36 aa of human tau protein.Cropped representative WB is shown (G). 
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a 7/3 ratio at pH7.4 (Figure 1C). Only in presence of high 
percentage of TFE (more than 60%), a solvent which has 
a dielectric constant lower than water and is widely used 
to mimic the hydrophobic environments of membranes, a 
slight propensity towards a coil-helix transition could be 
discernable in spectral profiles (Figure 1D). The shape and 
magnitude of CD curves from its reverse counterpart were 
not dissimilar from those of NH2htau (data not shown), 
just resembling the traditionally accepted “random coil” 
spectra, although conformational changes appeared more 
pronounced starting with lower TFE percentages (40%). 
Next, in order to evaluate the capability of 
both tau peptides dissolved in aqueous buffer to form 
amyloid-like fibrils, we carried out Thioflavin T (ThT)-
binding fluorescence assay. The kinetics of fiber 
growth in solution were monitored and time traces 
from NH2htau in the absence (red curve) and presence 
of LUV composed by total lipid brain extract (TLBE, 
green curve) were calculated. TLBE bilayers contain 
a physiologically important mix of lipid components 
-cholesterol, gangliosides, sphingolipids, isoprenoids in 
addition to both acidic and neutral phospholipids- making 
these bilayers a biologically-relevant model surface. As 
shown (Figure 1E), unlike the classical sigmoidal kinetic 
profile characterizing the ongoing Aβ1-40 fibrillogenesis 
which resulted in progressive 12-14 fold increase in ThT 
fluorescence intensity (black curve), no time-dependent 
emission signal was measured for NH2htau up to 48h. 
Relevantly, ThT measurements did not change over time 
showing the same signal recorded at time zero even after 
longer incubation, indicating that NH2htau was not prone 
to aggregate and was highly stable in solution. Likewise, 
reverse control counterpart did not show any ability 
to form amyloid fibrils in solution when tested both in 
the absence (blue curve) and presence of TLBE-LUV 
membrane model (cyan curve). 
Taken together the above data demonstrate that 
both NH2htau and its reverse control counterpart have 
intrinsically unstructured disordered nature (unfolded 
random coil) because they neither undergo any significant 
structural transition in different chemical and/or 
membrane-mimicking environments nor form aggregation 
fibers over time, although CD and ThT measurements do 
not completely exclude the possibility that the analyzed 
peptides might form amorphous and/or partially structured 
aggregates. Consistently with its monodisperse disordered 
structure in aqueous solution, SDS-PAGE Western blotting 
analysis with ad hoc devised 12A12 monoclonal antibody 
directed against the extreme N-terminal 26-36 aa of human 
tau protein (Figure 1F-1G), validated that the nature of 
NH2htau was mainly monomeric with a corresponding 
single band that migrated more slowly than expected 
in a calculated mass of 2.0 kDa, in line with previous 
studies of disease-related disordered proteins [16, 38]. In 
support of the finding that the prevailing molecular form 
of NH2htau under our experimental conditions appeared to 
be unaggregated, we found out that the overall proportion 
of soluble peptide in oligomers turned out to be low as its 
monomeric concentration increased. A lowly-populated 
fraction of aggregates of higher order oligomerization 
migrating around 35-50kDa was faintly detected only after 
prolonged exposition of high-performing PVDF transfer 
membranes, as shown in Supplementary Figure 1. 
Extracellular-added NH2htau stably interacts 
with authentic neuronal plasma membranes 
under physiological conditions and perturbs 
artificial biomembrane-like environments in a 
time-dependent manner
Despite being a highly soluble protein, full-
length tau has a strong propensity to interact with lipid 
membranes [39, 40, 41]. Indeed, although highly charged, 
it selectively inserts into synthetic anionic bilayer 
-likely owing to the attractive electrostatic interactions 
between the positively charged C-terminal microtubule 
(MT)-binding extremity and membrane lipids- inducing 
structural compaction [42, 43]. Besides, the negatively 
charged amino-terminal projection domain of tau has been 
shown to physiologically interact with more detergent-
resistant microdomains (lipid rafts) of the plasma 
membrane in a phosphorylation-dependent manner [16, 
44, 45, 46]. In view of these considerations, at first we 
set about testing the propensity of extracellular-added 
NH2htau to associate with biological plasma membranes 
in a native, physiological and cellular environment by 
means of morphological and biochemical experimental 
approaches. To this aim, live imaging experiments were 
first carried out on mature hippocampal primary neurons 
(15 DIV) after exposure to FITC-conjugated NH2htau 
(1µM) for short incubation times (5’-10’) and the binding 
of fluorescent peptide to neuronal cell membranes was 
revealed under non-permeabilizing conditions by TRITC-
cholera toxin subunits B which is known to specifically 
target the lipid raft microdomains. As shown in Figure 
2A-2H, NH2htau-exposed cultures exhibited a disperse 
punctate labeling which outlined the cell periphery and 
consistently colocalized with membrane-bound cholera 
toxin, indicating that this peptide was able to bind the 
neuronal plasma membrane near to these detergent-
resistant microdomains. This specific, dot-like pattern of 
immunoreactivity appeared even from shorter incubation 
times (5’) and was distributed both in close proximity 
to and away from somatic compartment (arrowheads 
and arrows point to non-synaptic and synaptic areas, 
respectively). Notably, not all structures were double-
labeled for components of both lipid rafts and NH2htau 
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Figure 2: NH2htau is adsorbed by native neuronal plasma membranes under in vitro physiological conditions and 
deeply perturbs membrane-like lipid bilayers in a time-dependent manner. A.-B.-C.-D.-E.-F.-G.-H. Fluorescence analysis 
(A-B-C-D) under non-permeabilizing conditions on hippocampal neurons (DIV15) in the presence or absence of the FITC-conjugated 
NH2htau. Live primary cultures were 30’exposed to FITC-conjugated NH2htau (1µM) (green channel) and then stained with TRITC-
conjugated cholera toxin subunit B (red channel). Nuclei were stained with DAPI (blue channel). Merge image shows the composition of two 
fluorescence channels. Untreated cultures were used as negative control (E-F-G-H). Notice that NH2htau displays a diffuse, dot-like pattern 
distributed both in close proximity to and away from somatic compartment (arrowheads and arrows point to non-synaptic and synaptic 
areas, respectively). Structures which are positive for components of lipid rafts but not for NH2htau (asterisks) are also present. Scale 
bar:5 µm. I.-J. Fluorescence analysis of purified hippocampal synaptosomal fractions in the presence or absence of the FITC-conjugated 
NH2htau. Isolated synaptosomes were dual-labeled (I) by staining with FM4-64 (50µM for 1’+ 30mMKCl for 90sec) (red channel) and 
with FITC-conjugated NH2htau (1µM) for 10’(green channel). Untreated synaptosomes were used as negative control (J). Overlay image 
(yellow, arrowheads) indicates colocalization of NH2htau and FM 4-64 in numerous granular spots. Few ring-like morphological structures 
(usually 1–3 µm in diameter) resembling spherical synaptosomes are labeled by NH2htau but not by membrane-bound FM4-64 dye .Scale 
bar:10 µm. K. Western blotting analysis (n=2) of isolated membrane-containing fractions from primary hippocampal neurons (15 DIV) 
exposed for 1h to NH2htau and its reverse (5µM). Untreated cultures and synthetic NH2 26-44 human tau peptide were used as controls. 
Immunoblotting was performed with 12A12 monoclonal antibody (26-36 aa) and with NR1 subunit antibody, to check the preparation 
purity. Cropped representative WB are shown. L.-M. DSC thermograms of LUV DMPC/DMPS 7/3 freshly prepared (black curve), LUV 
DMPC/DMPS 7/3 + NH2htau or reverse 20 µM each t = 0 (red curve), LUV DMPC/DMPS 7/3 + NH2htau or reverse 20 µM t = 24h (blue 
curve), LUV DMPC/DMPS 7/3 + NH2htau or reverse 20 µM t = 48h (green curve), LUV DMPC/DMPS 7/3 + NH2htau or reverse 20 µM 
each t = 72h (cyan curve). Values from deconvolution analysis of the peak profiles are reported in Table 1. 
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(asterisks) and, following incubation for short period 
of time and under not-saturable conditions, only a 
few rafts-positive axons as well as synaptic boutons 
were decorated with fluorescent NH2htau. To better 
investigate the specific association of NH2htau to the 
synaptic terminal ends, additional colocalization studies 
were carried out by double confocal analysis of isolated 
synaptosomal preparations marked with FM4-64 -a 
red fluorescent dye used to image functional synaptic 
terminals- in the presence of FITC-conjugated NH2htau 
(1µM). As shown in Figure 2I-2J, the punctate distribution 
of NH2htau overlapped with staining of the FM4-64 
-positive synaptosomes (arrowheads) supporting thus the 
finding that this extracellular-added peptide was able to 
accumulate on the plasma membrane of these subcellular 
compartments in exposed-neurons. 
Finally, biochemical experiments of subcellular 
fractionation aimed to isolate the membrane-containing 
portions from NH2htau-, reverse-treated and untreated 
primary hippocampal cultures followed by Western 
blotting analysis with our 12A12 tau antibody (26-36 
aa) (Figure 1F-1G), confirmed that the NH2htau was 
copurified with N-Methyl-D-aspartate (NMDA) Receptor 
subunit NR1-enriched fraction (Figure 2K) when 
extracellular-added to neurons. Control experiments 
were carried out to check the purity of preparation which 
turned out to be free of contaminations from other, non-
membranous compartments (Supplementary Figure 2). 
Altogether, these three different experimental approaches 
demonstrate that the NH2htau fragment is able to interact 
with genuine neuronal membrane and synaptic boutouns 
only after few minutes of exposure. 
Next, in order to investigate whether membrane-
bound NH2htau is also able to perturb lipid bilayer over 
time, we turned to differential scanning calorimetry (DSC) 
which is a highly sensitive non-perturbing technique 
useful for a thermodynamic and kinetic characterization 
of lipid/protein interactions in biomimetic models [47, 
48]. The potential of DSC experiments to provide useful 
information concerning peptide/membrane interactions 
is based on the fact that the heat capacity (Cp) profiles 
of the main transitions of mixed lipid/peptide systems 
can elucidate not only the effects of the peptide on the 
membrane but also its topological arrangement when 
inserted into the lipid matrix. In fact, as the enthalpy 
variations observed during the main lipid transitions 
are mainly due to the efficiency in the packing of the 
hydrocarbon tail, it’s possible to correlate the peptide-
induced reduction of the transition enthalpy of the bilayer 
to the extent of the interactions between guest molecules 
and the core of lipid membranes. Moreover, the main 
transition temperature is more sensitive to interactions 
involving the lipid headgroups, increasing when the 
membrane surface is involved in the interaction with the 
guest peptide [49, 50, 51]. To study the dynamic interaction 
of both NH2htau and its reverse peptide with lipid bilayer, 
we took advantage of the same experimental setting used 
to analyze another intrinsically disordered protein such as 
α-synuclein, which is also physiologically absorbed by 
raft microdomains onto the neuronal membrane surface 
and affects the thermotropic phase behavior of anionic 
lipid vesicles [52, 53]. Mixed acid-zwitterionic LUV 
composed by DMPC/DMPS (ratio 7:3) which mimic the 
composition of mammalian biomembranes [54]were thus 
used in our studies. This artificial biomembrane model 
undergoes spontaneous lipid phase segregation which 
can be observed by DSC thermograms. In particular, 
calorimetric heating scans displayed two endothermic 
peaks characterized by separate melting temperature (Tm) 
of transition centred at 27.2+/-0.1 °C and 28.7+/-0.1 °C 
which may be ascribed to DMPC- and DMPS-rich lipid 
domains, respectively (Figure 2L-2M, black curves). 
Gaussians deconvolution of DSC thermograms was then 
obtained (Table 1) to calculate the enthalpy change (ΔH) 
values corresponding to the two melting peaks of these 
distinct lipid domains (21.58+/-2.15 kJ mol-1 and 8.88+/-
0.9 kJ mol-1 for the DMPC- and the DMPS-rich lipid 
domains). The stability of the lipid bilayers over time was 
also tested at 25°C up to 72h and no significant change 
in the thermogram and thermodynamic parameters in 
DSC runs was detected (data not shown). Interestingly 
as shown in Figure 2L, the incorporation of the NH2htau 
into the DMPC/DMPS bilayers caused significant and 
time-dependent perturbations in their thermotropic phase 
behavior suggesting that this peptide was able not only 
to promptly associate to lipid membrane model but also 
to gradually induce profound structural changes in their 
packing. Indeed, immediately after the addition of 20 
µM NH2htau (Figure 2L red curve) to suspension, the 
phase segregation was more evident and interaction of 
NH2htau with the surface of the artificial membranes was 
clearly distinguished by the rise in the thermal transition 
temperature with partitioning of two discrete domains 
centred at 27.2+/-0.1°C and 29.2+/-0.1 °C, respectively. 
Besides, we did not observe any decrease in ∆H of 
the two domains at t = 0 (Table 1), indicating that this 
extreme N-terminal tau peptide at first interacted with lipid 
artificial membranes on the outside, stabilizing the more 
rigid DMPS-based regions. Similar results were obtained 
after 24 hours incubation of artificial biomembrane 
mimetics with NH2htau (Figure 2L, blue curve and Table 
1), as evidenced by slight changes in both enthalpy and 
temperature of the main transition in comparison to 
corresponding values at t = 0. However, a weak interaction 
between NH2htau peptide and the deep hydrophobic core 
of membrane appeared to be clearly discernable merely 
after 48 hours incubation (Figure 2L, green curve), as 
evidenced by diminution in both parameters of thermal 
transition temperature (from 29.4+/-0.1°C to 29.2+/-
0.2°C) and ∆H (from 9.24+/-0.9 kJ mol-1 to 8.64+/-0.8 kJ 
mol-1) of DMPS-rich domains when compared to t = 24h. 
A more pronounced reduction in total ∆H (from 28.95+/- 
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2.9 kJ mol-1 to 23.49+/- 2.3 kJ mol-1) was finally detected 
after prolonged incubation times (72 hours, Figure 2L 
cyan curve) in connection with a strong drop in the ∆H 
of the DMPC-rich domain (from 20.31+/-2.0 kJ mol-1 
to 16.94+/-1.7 kJ mol-1), as calculated by deconvolution 
analysis of the peaks (Table 1). Taken together these 
findings clearly indicate that: (i) this extreme N-terminal 
tau peptide enriches artificial membranes in more rigid 
DMPS-based regions at t = 0 and only later (t = 72h) 
shifts towards the more fluid, not-raft DMPC-based 
regions ; (ii) following its immediate adsorption on the 
surface of lipid membrane model, the deep interaction 
of NH2htau with the hydrocarbon region takes place 
only after longer incubation, suggesting that this peptide 
is more likely to be internalized after 48-72h exposure. 
Differently from NH2htau, its reverse counterpart showed 
a limited effect on the thermotropic phase behavior of 
DMPC/DMPS membranes displaying a poor tendency 
to interact with model membranes and to penetrate the 
lipid bilayer. Indeed, in parallel set of experiments we 
detected that the only interaction of this control peptide 
was with the DMPS-rich region on the surface of the 
membrane -as evidenced by the increase in thermal 
transition temperature of the second peak (from 29.2 
+/- 0.1 to 29.3+/- 0.1) - but that no concomitant decrease 
of the ∆H (Table 1) occurred up to 72h , suggesting the 
absence of any its obvious dynamic and stable interaction 
with the hydrophobic core of model membranes (Figure 
2M). To the point, it’s noteworthy that small differences 
in the spatial arrangement of aminoacids within a peptide 
sequence have been actually proved to cause big changes 
in the interaction of peptide with lipid membrane by 
affecting in particular the peptide orientation and/or the 
depth of membrane insertion. Therefore considering that: 
(i) the guest-induced decrease of ΔH is mainly ascribable 
to the insertion of the externally-added molecule into 
the hydrocarbon core of the bilayer and (ii) the NH2htau 
incorporation into the DMPC/DMPS membrane shows an 
increase in the gel-liquid crystal transition temperature of 
the bilayer with a decreased enthalpy change, it may be 
concluded that- following its immediate adsorption on the 
surface- only the NH2htau has the capability to stably and 
deeply interact with the lipid bilayer in a time-dependent 
manner. 
Collectively, these morphological and biochemical 
studies of live-imaging and subcellular fractionation along 
with biophysical DSC analyses on DMPC/DMPS lipid 
vesicles, demonstrate that NH2htau : (i) is able to interact 
within few minutes at least in part with lipid components 
located in both synaptic and non-synaptic areas of 
authentic neuronal plasma membranes; (ii) dynamically 
and spontaneously interacts with artificial membrane 
model, enriching earlier (up to 24h) the lipid biomimetic 
environments in the more rigid DMPS-based domains 
and being more likely internalized only after prolonged 
incubation times (48-72h) in correlation with its shift 
towards the more fluid, not-raft DMPC-based regions. 
Sublethal doses of extracellular NH2htau induce 
prompt perturbation in K+-evoked calcium 
dynamics on isolated hippocampal synatopsomes
Properly controlled Ca2+ homeostasis is crucial for 
physiological maintenance of neuronal integrity as well 
as for survival and synaptic plasticity by controlling the 
release of neurotransmitter, membrane excitability and 
network activity. Consequently, perturbations in Ca2+ 
signaling have been proposed as one of the earliest age-
related event underlying the synaptic pathology occurring 
in the AD and leading eventually to neurodegeneration 
Table 1: Thermodinamic parameters of samples containing LUV DMPC/DMPS 7/3 ratio and NH2htau or its reverse 
over time.
Sample T1 (°C) ∆H1(kJ mol-1) T2 (°C) ∆H2(kJ mol-1) ∆Htot(kJ mol-1)
DMPC/DMPS 7/3 200 µM 27.2 ± 0. 1 21.58 ± 2.15 28.7 ± 0. 1 8.88 ± 0. 9 30.46 ± 3. 0
DMPC/DMPS 7/3 200 µM  
NH2htau  20 µM t=0 h 27.2 ± 0. 1 22.80 ± 2.3 29.2 ± 0. 1 9.68 ± 1. 0 32.48 ± 3. 2
DMPC/DMPS 7/3 200 µM 
NH2htau 20 µM t=24 h 27.2 ± 0. 1 23.05 ± 2.3 29.4 ± 0. 1 9.24 ± 0. 9 32.29 ± 3.2
DMPC/DMPS 7/3 200 µM 
NH2htau 20 µM t=48 h 27.2 ± 0. 1 20.31 ± 2.0 29.2 ± 0. 1 8.64 ± 0. 8 28.95 ± 2.9
DMPC/DMPS 7/3 200 µM 
NH2htau 20 µM t=72 h 27.2 ± 0. 1 16.94 ± 1.7 29.2 ± 0. 1 6.55 ± 0. 6 23.49 ± 2.3
DMPC/DMPS 7/3 200 µM 
 reverse  20 µM t=0 h 27.2 ± 0. 1 20.78 ± 2.1 29.2 ± 0. 1 8.07 ± 0. 8 28.85 ± 2.8
DMPC/DMPS 7/3 200 µM 
 reverse  20 µM t=24 h 27.2 ± 0. 1 21.63 ± 2.2 29.3 ± 0. 1 9.25 ± 0. 9 30.88 ± 3.1
DMPC/DMPS 7/3 200 µM 
 reverse  20 µM t=48 h 27.2 ± 0. 1 22.14 ± 2.2 29.3 ± 0. 1 9.4 ± 0. 9 31.54 ± 3. 1
DMPC/DMPS 7/3 200 µM 
 reverse  20 µM t=72 h 27.2 ± 0. 1 23.30 ± 2.3 29.3 ± 0. 1 8.54 ± 0. 8 31.84 ± 3.2
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[55, 56]. Having established that neuronal plasma 
membrane is a plausible site of action for extracellular 
N-terminally truncated tau species -which are more likely 
to be produced inside neurons by intracellular cleavage of 
full length-protein and then released into the extracellular 
space [13, 14]- we investigated the effects induced by 
acute application of low concentration of extracellular 
NH2htau and its reverse peptide on both the basal and 
the KCl-evoked Ca2+ dynamics turning to quantitative 
imaging with highly-specific Ca2+-sensitive fluorescent 
indicator. Besides, since changes of intracellular calcium 
homeostasis in nerve terminals directly trigger the 
discharge of synaptic vesicles and glutamate release 
evoked by K+-depolarization [57, 58, 59], we performed 
our assays on isolated hippocampal pinched-off nerve 
terminals, so-called synaptosomes, which are targeted 
by extracellular NH2htau (Figure 2) and have been 
proved to be particularly useful for biochemical studies 
of presynaptic stimulus-secretion coupling [60]. To this 
aim, purified synaptosomal preparations were preloaded 
with Fluo3 dye and then 5 min exposed to NH2htau or its 
reverse counterpart at 1 µM each, a concentration which 
does not cause any significant in vitro neuronal death up 
to 72h -as we previously assessed by MTT assay and 
Western blotting detection of active cleaved caspase-3 
(Supplementary Figure 3)- and more closely mimics 
the in vivo pathological range of release-competent 
(i.e. soluble and microtubule unbound) amount of 
intracellular tau [61, 62, 63, 64]. Upon chemically-induced 
depolarization with 30mM KCl, each Ca2+ transient for 
three different experimental groups (saline-treated ctrl, 
NH2htau- and reverse-treated) was measured and the 
intensity and kinetics of the intrasynaptosomal Ca2+ 
changes produced by extracellular high [K+] were then 
visualized as a characteristic rapid rise to peak followed 
by a descending and apparent plateau phase, consistently 
with previous results [65]. Quantitative averaged data of 
fluorescence intensity (peak amplitude, ∆F) and of kinetic 
parameters (peak to baseline; baseline to peak; overall 
duration of signal) are shown in Figure 3. Following 
K+-stimulation(Figure 3A-3B-3C-3J), synaptic fractions 
acutely exposed to NH2htau displayed a pronounced 
potentiation (+35% and 36%, compared to both reverse- 
or untreated controls) in evoked increase of free-Ca2+ 
fluorescence intensity (∆F NH2htau: pixel intensity 
72, 07% +/-12, 33 SD, +/- 2, 4 SEM n = 58, one-way 
repeated-measures ANOVA followed by Bonferroni post-
hoc test ***p <0, 0001) in comparison to both reverse- 
or untreated controls. On the contrary (Figure 3D-3E-
3F-3G-3H-3I-3J), application of the reverse peptide 
failed to produce any significant change in magnitude 
of K+-induced Ca2+ peak height (-1%) (∆F reverse: pixel 
intensity, 53, 17% +/-14, 21 SD, +/- 1, 8 SEM n = 66, one-
way repeated-measures ANOVA followed by Bonferroni 
post-hoc test p >0, 05) which did not significantly differ 
from untreated controls (∆F ctrl: pixel intensity, 52, 61% 
+/-10, 68 SD, +/- 1, 3 SEM n = 98). Further, as shown 
by kinetic analyses reported in Figure 3K, all the kinetic 
parameters displayed a significative difference when 
the NH2htau group was compared to both reverse and 
untreated controls. Indeed, the rise in synaptic Ca2+ signal 
(baseline to peak: NH2htau 2, 2 s +/-0, 42 SD, +/-0, 08 
SEM; ctrl 2, 02 s +/-0, 21 SD, +/- 0, 02 SEM; reverse 
2, 03 s +/-0, 34 SD, +/-0, 03 SEM) was significantly 
different among the three different experimental groups 
(+10% NH2htau vs ctrl and reverse, one-way repeated-
measures ANOVA followed by Bonferroni post-hoc test 
**p <0, 01; -0, 4% ctrl vs reverse p >0, 05). The fall of 
synaptic Ca2+ transient (-22 % vs ctrl; -26 % vs reverse) as 
well as its time course (-21 % vs ctrl; -24 % vs reverse) in 
nerve endings preparations exposed to NH2htau (NH2htau: 
peak to baseline 44, 75 s +/-16, 25 SD, +/-2, 7 SEM one-
way repeated-measures ANOVA followed by Bonferroni 
post-hoc test ***p <0, 0001; duration 47 s +/-15, 53 SD, 
+/-2, 8 SEM n = 58 one-way repeated-measures ANOVA 
followed by Bonferroni post-hoc test ***p <0, 0001) 
were significantly reduced compared to both reverse-and 
untreated controls. Conversely, reverse peptide (reverse: 
peak to baseline 60, 54 s +/-19, 62 SD, +/-3, 4 SEM; 
duration 62, 57 s +/-20, 15 SD, +/-3, 4 SEM n = 66 ) did 
not provoke any significant change in kinetic parameters 
(peak to baseline -4% vs ctrl one-way repeated-measures 
ANOVA followed by Bonferroni post-hoc test p >0, 
05; duration -4% vs ctrl one-way repeated-measures 
ANOVA followed by Bonferroni post-hoc test p >0, 05) in 
comparison to untreated control (ctrl: peak to baseline 57, 
59 s +/-14, 89 SD, +/-1, 7 SEM; duration 59, 61 s +/-14, 
21 SD, +/- 1, 7 SEM). Importantly, no significant global 
change in Ca2+ amplitude over baseline was detected in 
parallel assays when hippocampal synaptosomes (up 
to 30’; data not shown) and mature (15 DIV) primary 
neuronal cultures as well (up to 1h; data not shown) were 
exposed to extracellular NH2htau and reverse peptide both 
used at the same experimental concentration (1 µM) but in 
the absence of KCl stimulus (resting conditions). To this 
point, we did not measure any significant variation in Ca2+ 
signal throughout the recording times ruling out thus the 
possibility that its external application could lead to other 
calcium-affecting mechanisms previously described for 
preaggregated and unaggregated full-length tau species, 
including ionic pore formation and membrane leakage 
[66, 67], activation of specific cell surface receptors [62] 
or inhibition of plasma-membrane Ca2+-ATPase (PMCA) 
[68].
 Taken together, our data from Ca2+ functional 
imaging demonstrates that:(i) acute treatment with low, 
sublethal doses of extracellular-applied NH2htau is not 
able to modify the resting Ca2+ level but affects both the 
magnitude and the kinetic parameters of ionic intracellular 
signaling evoked by chemically-induced depolarization of 
the synaptic neuronal compartments; (ii), the amplitude of 
K+-evoked Ca2+ transient is greater in synaptosomes when 
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Figure 3: Acute administration of sub-toxic doses of NH2htau induces perturbation in regulation of K
+-evoked 
intracellular calcium dynamics in isolated hippocampal synaptosomes. Changes in K+-evoked Ca2+ levels induced by NH2htau 
and its reverse counterpart were assessed in Fluo-3 loaded hippocampal synaptosomes exposed to NH2htau (1µM), its reverse peptide 
(1µM), and saline (CTRL) 5 min before KCl (30mM) stimulation. A.-D.-G. Upper row: wide field images of treated synaptosomes. 
Baseline pre-stimulus is the image immediately before the fluorescence increase towards the peak. Peak is the image showing the highest 
fluorescence intensity. Baseline post-stimulus is the image immediately after that the post-stimulus baseline is established. Lower row: false 
color image (fire palette; Spectral Difference Image) showing the fluorescence intensity of the difference image. Brighter spots correspond 
to functional presynaptic terminals. Difference image is the subtraction of the baseline pre-stimulus image from the peak one. B.-E.-H. 
Normalized traces of fluorescence intensity spatial profiles derived from the line shown in A, D, and G. Green line refers to the baseline pre-
stimulus image. Red line refers to the peak image. Cyan line refers to the baseline post-stimulus image. Note the relative fluorescence height 
intensity of the peak image (red line) which appears spatially distributed to partially fused multiple sites. C.-F.-I. Representative traces 
of fluorescence time courses derived from the three experimental groups. KCl black arrows indicate the time of the stimulus addition. J. 
Comparison, among the three experimental groups, of the average percentages of the fluorescence intensity difference between the peak and 
the baseline pre-stimulus values. Note the statistically significant increase of calculated value from NH2htau in comparison to those from 
the reverse and CTRL groups (one-way ANOVA followed by Bonferroni post-hoc test ***p<0,0001 versus NH2htau). K. kinetic analysis 
of the fluo-3 intensity time-course: baseline to peak, i.e. time for the rate of signal rise; peak to baseline, i.e. time for the rate of signal 
decay; total duration, i.e. the overall time from baseline pre-stimulus to baseline post-stimulus. Data were derived from five independent 
experiments. In each experiment two coverslips for each experimental group were analyzed. Values are means of at least four independent 
recordings and statistically significant differences were calculated by one-way ANOVA followed by Bonferroni post-hoc test (**p<0,01; 
***p<0,0001 versus NH2htau). Scale bar: 20µm.
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exposed to NH2htau but declines to a stable plateau more 
quickly (i.e higher and shorter signal) than in the other two 
experimental groups (reverse- and saline-treated controls); 
(iii) this effect is specific because its reverse sequence is 
actually inactive in perturbing either basal or stimulated 
Ca2+ homeostasis when compared to saline-exposed 
untreated controls.
Extracellular-added NH2htau acutely inhibits 
K+-induced FM1-43 destaining and presynaptic 
glutamate release in hippocampal synaptosomal 
preparations
Owing to potent relationship between Ca2+ 
and exocytosis, small changes in Ca2+ influx during 
a presynaptic potential action are highly effective in 
modulating the neurotransmitter output at synapses [69]. 
Glutamate is the primary excitatory neurotransmitter in the 
brain playing an important role in hippocampal-dependent 
learning and memory and deregulation of glutamatergic 
synaptic transmission is considered a primary step of 
synaptic failure occurring in the pathogenesis of AD [70]. 
In view that our results showing an early modulatory effect 
of NH2htau on K
+-evoked regulation of intracellular Ca2+ 
(Figure 3) hinted at possible alterations in Ca2+-dependent 
mechanisms underlying synaptic activity, we evaluated the 
acute effects evoked by the extracellular addition of either 
NH2htau and its reverse sequence (1 µM each) on live 
dynamics of vesicles release from isolated nerve terminals 
(i.e. synaptosomes) of mature (15 DIV) hippocampal 
neurons by means of functional FM1-43 fluorescence 
imaging. FM1-43 styryl dye is more fluorescent when 
partitioned in membranes, so its release from synaptic 
vesicles can be measured as a monoexponential loss 
in signal which actually reflects the rate of exocytosis 
occurring at nerves terminals. Although this protocol is 
unable to discriminate glutamatergic from GABAergic 
synapses, its activity-dependent unloading is widely used 
to study the properties of presynaptic release on purified 
synaptosomal preparations, providing thus a direct 
measure of their in vitro secretory function [59, 71, 72, 
73]. After 5 min exposure to NH2htau, its reverse sequence 
and saline, the decay of FM1-43 fluorescence evoked by 
synaptosomes stimulation with high-potassium (30 mM 
KCl) was measured and quantitative analysis of live 
imaging data from the three different experimental groups 
is shown in Figure 4A-4B-4C-4D-4E-4F-4G-4H. Results 
clearly indicate that short-term application of subtoxic 
doses of extracellular NH2htau caused a significant 
reduction of pre-synaptic FM1-43 destaining (NH2htau: 
12, 42 %+/- 4, 7 n = 90, one-way repeated-measures 
ANOVA followed by Bonferroni post-hoc test **p < 0, 
01) in individual hippocampal axonal terminals which 
displayed severe deficits in vesicles release dynamics 
when compared to both reverse- and untreated controls 
(-36, 56 % vs ctrl; -30, 94 % vs reverse). Conversely, 
reverse peptide did not provoke any appreciable change in 
activity-dependent dye unloading (reverse: 17, 98 % +/- 6, 
1 n = 86) and reverse-treated nerve terminal preparations 
did not significantly differ (-8%) from untreated controls 
(ctrl: 19, 58% +/- 3, 2 n = 90, one-way repeated-measures 
ANOVA followed by Bonferroni post-hoc test p >0, 05). 
Of note, when hippocampal synaptosomes were exposed 
to extracellular NH2htau used at the same experimental 
concentration (1 µM) but in the absence of KCl stimulus 
(resting conditions, saline-exposed), we did not detect 
significant differences (Figure 4G) in comparison to an 
untreated and saline-exposed group ruling out thus the 
possibility that this extracellular-added peptide might have 
a destaining effect per se .
To further investigate the nature of potent in vitro 
inhibitory effect shown by NH2htau on presynaptic 
compartment of hippocampal neurons, high-sensitive 
radioactivity-based assays of glutamate release were also 
carried out according to standard procedure [74, 75]. 
To this aim, isolated nerve endings preloaded with [3H]
D-aspartate ([3H]D-Asp) -which allows to measure the 
neurotransmitter exocytosis avoiding drawbacks due to 
its enzymatic degradation- were incubated with synthetic 
NH2htau or its reverse counterpart (1, 10, 100nM) and 
then superfused with mild depolarizing stimulus (12 mM 
KCl; equiosmolar replacement of Na+) in order to elicit the 
Ca2+-dependent, exocytotic-like release of the radioactive 
tracer [76, 77, 78]. As shown in Figure 4I, transient and 
short-term exposure (-90 s) of synaptosomal terminals to 
nanomolar concentrations of NH2htau caused a dramatic 
and statistically significant inhibition of 12 mM K+-evoked 
tritium overflow in a concentration-dependent manner, the 
maximum of inhibition (-38, 3%) being observed when 
the peptide was added at 100 nM (NH2htau: 1 +/- 0, 09 n 
= 11 ANOVA followed by Bonferroni post-hoc test ***p 
< 0, 0001 vs ctrl). On the contrary, reverse peptide even if 
used at the highest experimental concentration (100 nM) 
was completely inactive in modulating the exocytotic-
like glutamate release (reverse: 1, 63 +/-0, 09 n = 11) and 
treated samples did not significantly differ from saline-
exposed untreated controls (ctrl 1, 62 +/- 0, 06 n = 11). 
No significant effect on spontaneous basal glutamate 
release was detected in isolated synaptosomes upon long-
term incubation with NH2htau and its effect on K+ evoked 
neurotransmitter exocytosis was abrogated by incubation 
in Ca2+-free milieu or by pretreatment with membrane-
permeant ion chelator 1, 2-bis-(2-aminophenoxy)
ethane-N, N, N’, N’-tetraacetic acid tetra(acetoxymethyl) 
ester (BAPTA/AM)BAPTA, suggesting that the 
presynaptic action of NH2htau is strictly Ca
2+- dependent 
(Figure 4I).
 Importantly, these functional changes at synaptic 
terminals occurred within few minutes of exposure, in 
agreement with prompt and marked tendency of NH2htau 
to interact with biomimetic and cell-surface membranes as 
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we previously detected by morphological, biochemical and 
biophysical studies (Figure 2). Besides, the extracellular-
added NH2htau, but not its reverse counterpart, was 
able to alter the K+- stimulated functional properties in 
neurotransmitter secretion of hippocampal neurons in the 
absence of any appreciable cell injury because the loss in 
synaptic components along with the structural changes in 
neuritic architecture and the reduction in mitochondrial 
density were measured only later, after 48h incubation 
times (see below) . 
Collectively these experiments, carried out on 
isolated hippocampal synaptosomes by Ca2+-indicator dye 
measures and neurotransmitter exocytosis assays, points 
to a direct causal link between depolarization-dependent 
defects in Ca2+ handling and early presynaptic modulatory 
effect of extracellular NH2htau on glutamatergic 
Figure 4: NH2htau acutely inhibits the K
+-stimulated presynaptic vesicles release and glutamate exocytosis in purified 
synptosomal preparations. A.-B.-C.-D.-E.-F.-G.-H. K+-induced destaining of FM1-43 dye on isolated nerve terminals from mature 
(15 DIV) hippocampal neurons exposed to NH2htau (1µM), its reverse peptide (1µM), and saline (CTRL) 5 min before KCl (30mM) 
stimulus addition. A.-C.-E. Upper row: wide field images of treated synaptosomes. Lower row: false color vertically corresponding images 
(fire palette) which show the fluorescence intensity. Brighter spots correspond to functional presynaptic terminals. First is the image before 
KCl administration. Last is the image when the after-stimulus baseline is established. Difference is subtraction of the last image from the 
first one. Note that the yellow color is below the saturation level (i.e.white color). B.-D.-F. Representative traces of destaining time courses 
derived from the three experimental groups. G. Normalized, aligned and averaged fluorescence intensity traces derived from the three 
experimental groups (25 traces each) plus two saline(-KCl) additional controls. One, in the absence of both treatments and KCl stimulus, 
representing the fluorescence bleaching rate of our experimental setting. The other one, in the presence of NH2htau (1µM) and with saline 
added, showing that NH2htau alone is not able to induce significant destaining effects. Trend lines (black lines) superimposed to fluorescence 
intensity values of three experimental groups were calculated by polynomial fitting. H. Comparison of the average destaining percentage 
of the fluorescence intensity among the three experimental groups. In each experiment(n=5) two coverslips for each experimental group 
were analyzed. Values are means of at least three independent recordings and statistically significant differences were by one-way ANOVA 
followed by Bonferroni post-hoc test (**p<0,01versus NH2htau). Scale bar:15µm. I. The overall dose-effect of the NH2htau action (1-10-
100nM) on glutamate release was evaluated by high-sensitive radioactive-based measure of depolarization-evoked release of [3H]D-Asp. 
Reverse sequence, used at the highest concentration(100nM) and saline-exposed untreated controls were also included. The K+-evoked 
tritium overlow is expressed as % of 12 mM KCl-evoked [3H]D-aspartate overflow versus saline-exposed untreated ctrl.Values are means 
of at least five independent experiments and data were considered statistically significant for p < 0.05 at least (**p < 0,01; ***p < 0,0001 
versus saline-exposed untreated ctrl, one-way ANOVA followed by Bonferroni post-hoc test).
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neurotransmission demonstrating that: (i) the inhibitory 
action on depolarization-stimulated glutamate 
exocytosis induced by short-term external application 
of low, sublethal doses of NH2htau is accompanied by 
concomitant alteration in local Ca2+ dynamics in nerve 
endings; (ii) the peak amplitude and kinetic parameters of 
Ca2+current evoked by K+ stimulation develop respectively 
at a greater rate but decay to a less long-lasting plateau in 
NH2htau-exposed in nerve endings compared with control 
ones (i.e higher and shorter signal), resulting in an overall 
decrease in neurotransmitter release ; (ii) these changes 
are specific for NH2htau because its reverse sequence does 
not afford any significant effect either on stimulated Ca2+ 
signaling or on glutamate exocytosis when compared to 
saline-exposed untreated controls.
Deterioration in presynaptic terminals, neuritic 
degeneration, microtubule collapse and reduction 
of mitochondrial density are detected in living 
hippocampal neurons only after long-term 
exposure to sublethal doses of NH2htau
Structural alterations in synaptic terminals, 
instability of microtubules, dendritic retraction, 
mitochondrial abnormalities are all hallmarks of 
Figure  5: Long-term application of NH2htau induces a marked and selective loss of exocytotic presynaptic vesicles 
proteins in cultured hippocampal neurons. A.-B. Western blotting analysis (n=12) was carried out on equal amounts of total protein 
extract (40µg) from mature hippocampal primary neurons (DIV15) exposed for 48h to increasing subtoxic concentration (1-2µM) of 
NH2htau and its reverse control sequence. Immunoblots (A) were probed with antibodies against several presynaptic- (α-synuclein, synapsin 
I, synaptosomal-associated protein 25 SNAP-25, synaptophysin, vesicular glutamate transporter 1 vGLUT1 , synaptic vesicle protein 2 
SV2, dynamin, synaptotagmin) and post-synaptic markers (N-Methyl-D-aspartate NMDA Receptor Subunit NR1, postsynaptic density 
protein 95 PSD95) and against not-synaptic proteins located in trans-Golgi network and endoplasmic reticulum (golgin-97 and calnexin). 
Cropped representative WB are shown. Densitometric quantification of immunoreactivity levels (B) was calculated by normalizing the 
values on the β-actin intensity and expressed as ratio respect to corresponding ctrl values.Values are means of at least nine independent 
experiments and statistically significant differences were calculated by one-way ANOVA followed by Bonferroni post-hoc test (*p < 0,05; 
**p<0,01; ***p<0,0001 versus untreated ctrl). 
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neuronal pathology playing a critical role in promoting 
cognitive dysfunction during the AD onset/progression 
and appearing prior to frank cell death [79]. Therefore, 
by Western blotting on total protein extracts and 
immunocytochemistry analyses, we investigated 
the expression level and subcellular distribution of 
different cellular markers of synaptic, cytoskeleton and 
mitochondrial compartments after administration of 
NH2htau (1-2µM) to hippocampal neuronal cultures for 
increasing incubation times (up to 48-72 h). Interestingly 
(Figure 5A-5B), we noticed only after 48h cultures 
treatment a significant and dose-dependent decline 
in selected proteins which are mainly located in the 
presynaptic compartment and are involved in local 
turnover of synaptic vesicles and/or Ca2+-triggered 
neurotransmitter release, such as α-synuclein, synapsin 
I, synaptosomal-associated protein 25 (SNAP-25), 
synaptophysin and vesicular glutamate transporter 
1(vGLUT1). Importantly, no discernable change was 
detected at earlier incubation times (1-3-6-12-24h, data 
not shown) ruling out the possibility that the diminution 
in functional release of glutamate induced by the acute 
administration of NH2htau on isolated hippocampal 
synaptosomes -as we showed in Figure 4- could be ascribed 
to modifications in expression levels of these relevant 
presynaptic proteins which control the Ca2+-coupled 
neurotransmitter exocytosis at nerve endings. Others 
presynaptic proteins -such as synaptic vesicle protein 2 
(SV2), dynamin, synaptotagmin- were unmodified, in line 
with the in vivo evidence that presynaptic proteins are not 
equally affected in AD brains [80, 81, 82]. Conversely, 
the expression level of two major postsynaptic proteins 
-N-Methyl-D-aspartate (NMDA) Receptor subunit NR1 
and postsynaptic density protein 95 (PSD95) - did not 
change or even significantly increased, likely due to 
reactive/compensatory mechanisms reminiscent of those 
occurring in vivo during progression of AD pathology [83, 
84]. Other postsynaptic proteins, such as NMDAR2A/B 
and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) Receptor subunit GluR1/5, were also 
unaffected throughout our experimental conditions (data 
not shown). No significant alterations in the intracellular 
amount of not-synaptic proteins located in different 
subcellular compartments- including specific markers of 
trans-Golgi network and endoplasmic reticulum such as 
golgin-97 and calnexin- were contextually found. 
Furthermore morphological quantitative studies 
(Figure 6A-6B-6C-Supplementary Figure 4), in addition 
to confirming the loss of selective pre-synaptic proteins 
detected in above-mentioned biochemical analyses, 
revealed that a concomitant disruption of cytoskeleton 
took place in NH2htau-treated hippocampal cultures 
which displayed a simplification in network of neuronal 
processes along with an evident corruption/diminution 
in array of microtubule track (length and assembly). A 
pronounced decrease in immunoreactivity of MAP-2, a 
microtubule-associated protein largely used to trace the 
integrity of the neuritic network, was clearly evident in 
NH2htau-treated neuronal cultures when compared to 
control and reverse groups (one-way repeated-measures 
ANOVA followed by Bonferroni post-hoc test ***p 
<0, 0001) in concomitance with a marked drop in the 
density of puncta positive for synaptophysin, a specific 
marker for presynaptic membrane vesicles (one-way 
repeated-measures ANOVA followed by Bonferroni 
post-hoc test ***p <0, 0001) (Figure 6A, Supplementary 
Figure 4C-4D). The loss in MAP-2 staining turned out 
to be mostly localized to neurites of thin calibers (Figure 
6A, arrows) which appeared distorted, fragmented 
and decorated with interspersed bead-like varicosities 
whereas the larger processes (Figure 6A, arrowheads) 
were still present and appeared uninjured. Moreover, after 
staining of neuron-specific βIII-tubulin, NH2htau-treated 
neuronal cultures showed in comparison to control and 
reverse groups an evident neuritic dystrophy (one-way 
repeated-measures ANOVA followed by Bonferroni post-
hoc test ***p <0, 0001) involving both high and low 
calibers processes (Figure 6B, arrows and arrowheads 
respectively, Supplementary Figure 4A). Destabilization 
and reduction in length of cellular microtubules occurred 
in concomitance to a net decrease in dotted labeling for 
α-synuclein(one-way repeated-measures ANOVA followed 
by Bonferroni post-hoc test ***p <0, 0001, Supplementary 
Figure 4B ), a presynaptic protein which is known to 
be also severely affected in several neurodegenerative 
tauopathies including AD [85]. Besides, a significant 
reduction in density of COX-1- positive mitochondria 
was also clearly appreciable in NH2htau-exposed neuronal 
cultures (one-way repeated-measures ANOVA followed by 
Bonferroni post-hoc test ***p <0, 0001, Supplementary 
Figure 4E-4F), just resembling the retrograde degeneration 
or “dying-back neuronal death” as detectable at prodromal 
AD stages [86, 87, 88]. In particular, mitochondria co-
located (Figure 6C, asterisks in reverse-treated and 
control groups) or juxtaposed to synaptic sites (Figure 
6C, arrowheads and arrows in opposition) appeared 
mainly affected in primary cultures upon long-term 
treatment with extracellular NH2htau. In line with 
previous findings reporting a causal relationship between 
tau malfunction, depletion of synaptic mitochondria and 
loss of synaptic markers [89], the impaired trafficking of 
these organelles which were likely no longer transported 
along compromised axonal projections towards terminal 
ends [90] occurred along with progressive and delayed in 
vitro presynaptic deterioration, as displayed by contextual 
decline in synapsin-I immunoreactivity. Importantly, 
in spite of these neuritic and synaptic degenerative 
alterations, only very few neurons displayed an evident 
nuclear heterochromatin, indicating that most of these 
pathological changes occurred before an overt neuronal 
death (Supplementary Figure 3). Finally, no changes in 
global cellular integrity/viability (Supplementary Figure 
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3) were found in untreated and reverse-treated controls 
used at the same experimental conditions (concentration 
and time incubation), although we detected a slight 
variability in the latter experimental group in agreement 
with previous findings reporting a quantifiable but 
not statistically-significant interfering response in 
hippocampal neurons exposed to other backward-reading 
sequence peptides such as the reverse Aβ peptide [91]. 
 Taken together, these studies suggest that: (i) 
chronic exposure of mature hippocampal primary neurons 
to low and sublethal doses of extracellular NH2htau 
recapitulates important features of in vivo pre-symptomatic 
stages of AD neuropathology resembling the dying-back 
mechanisms of cell degeneration ; (ii) NH2htau -but not 
its reverse sequence- is able to specifically interfere with 
structural stability of presynaptic terminals only after 
chronic treatment of cultures (48-72h) in concomitance 
with pronounced perturbations in number of resident 
mitochondria and/or cytoskeleton organization.
NH2htau peptide shows a higher propensity 
to assume less compacted conformers than its 
reverse counterpart: conformational flexibility 
may account for their divergent in vitro biological 
effects
Proteolytic cleavage of tau alters its structure, 
functional capacity and propensity to aggregation 
[1]. Nevertheless, given their intrinsically flexible 
nature, tau and its truncated forms do not retain a fixed 
3D structure but fluctuate among a large number of 
different configurations and, consequently, relative 
structural studies turn out to be problematic and cannot 
be performed by means of standard techniques, such 
as X-ray diffraction and electron microscopy [92, 93, 
94, 95]. In this context, small angle X-ray scattering 
(SAXS) is one of the few biophysic approaches which 
is able to provide detailed structural information on this 
protein, allowing a quantitative characterization of its 
conformational polydispersity [93, 94, 95]. Accordingly, 
Figure  6: Distortion of the dendritic tree, microtubule breakdown and mitochondria loss occur in concomitance 
with decline of presynaptic proteins density in living hippocampal neurons chronically exposed to NH2htau. A.-B.-C. 
Confocal microscopy analysis of double immunofluorescence carried out on mature hippocampal primary neurons (DIV15) exposed for 
48h to NH2htau and its reverse control sequence (1µM). Merge images show the overlay of the three fluorescence channels, Differential 
Interference Contrast (DIC; gray channel) enables the visualization of the neuritic network, DIC Merge is the composition of the three 
fluorescence and of the DIC channels. (A): presynaptic synaptophysin (green channel) and dendritic MAP-2 (red channel). Nuclei (blue) 
were stained with Hoechst 33258 (0.5 mg/ml). Arrowheads and arrows point to MAP2- positive neurites of larger and smaller caliber, 
respectively. (B): presynaptic α-synuclein (green channel) and neuron-specific cytoskeletal beta III tubulin (red channel). Arrowheads and 
arrows point to beta III tubulin-positive neurites of larger and smaller caliber, respectively. (C): presynaptic synapsin I (green channel) and 
mitochondrial marker COX I (red channel). Arrowheads point to synapsin I-labeled presynaptic spots and arrows point to COX I -positive 
mitochondrial structures. In the merge, DIC and DIC-Merge channels, arrowheads and arrows appear in opposition to give evidence to 
mitochondria resident at juxstaposed presynaptic sites. Asterisks mark typical punctuate structures immunoreactive for both synapsin I 
and COX I (yellow dots) representing mitochondria which are localized to presynaptic sites (i.e.synaptic mitochondria). Note the loss of 
double-stained synapsin I/COX I puncta and the decrease of juxstaposed presynaptic sites/mitochondria in the NH2htau-treated cultures. 
Images are representative of at least three independent experiments. Scale bar: A=20 µm ;B-C=10 µm. 
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the SAXS method has been widely employed in recent 
years to study the overall structure of both full length tau 
and its truncated forms [95, 96, 97, 98, 99, 100, 101] and 
also to characterize other neuropathologically-relevant 
small peptides composed of only few tens of residues 
such as the neurotoxic Aβ1-42 (42 aminoacids) [102] and 
the chemically unfolded Angiotensin II (8 aminoacids) 
[103]. However, at variance with C-terminal fragments 
that have been extensively studied [95, 99, 104], very little 
is known about NH2-terminal fragments of tau protein 
whose structural characterization can provide a better 
understanding of their potent neurotoxic role [13, 33, 34, 
105]. 
Here, we used SAXS to investigate the overall 
conformation of the NH2htau and its reverse sequence 
peptide. Figure 7a-7b displays the processed scattering 
curves I(s) of two measured tau constructs with both 
profiles appearing featureless, as expected for a flexible 
and unstructured peptide. Their flexible nature was also 
confirmed by the Kratky plot (s2I(s) as a function of s) 
which is traditionally employed to qualitatively identify 
disordered protein states (Figure 7c-7d, for NH2htau and 
its reverse respectively ) [92, 93, 95, 97, 98, 99, 106]. 
As expected, Kratky plots (Figure 7c-7d) were not bell-
shaped with a clearly defined maximum. For both tau 
peptides, s2I(s) monotonously increased up to reach a 
plateau at high s values -a behavior which resembleed that 
of an ideal Gaussian chain [106]- further confirming their 
unstructured nature. The gyration radius RG of NH2htau 
and its reverse peptide were then estimated by using the 
Guinier approximation -according to which the scattering 
intensity has a Gaussian shape at small s (s<1.3/RG) [92, 
93, 94, 95, 97, 98, 99, 106]- and the calculated Guinier 
plot (lnI(s) vs s2) is reported in Figure 7e-7f respectively. 
As shown by a linear fit of the data, we obtained RG = 
1.32±0.02 nm for NH2htau26-44 and 1.23±0.02 nm for its 
reverse sequence peptide. Similar results were found by 
using the Debye’s approximation (data not shown) and the 
RG values are summarized in Table 2. 
An important metric holding for unstructured 
proteins and peptides is given by the Flory equation that 
correlates RG with the length of the peptides [103]:
RG = R0N
ν (eq. 1)
where N is the number of aminoacids, R0 is a 
constant that depends on the persistence length of the 
chain and ν = 1/2 for a Gaussian chain. For R0 = 2.54±0.01 
nm and v = 0.598±0.028, Eq. 1 well describes the behavior 
of unfolded proteins and peptides ranging between 16 and 
549 residues [103]. By using eq. 1, a theoretical value of 
RG = 1.18±0.03 nm could be estimated for both peptides 
and this value was consistent within one standard deviation 
with that we measured for the reverse sequence, again 
endorsing its flexible and disordered nature. Conversely, 
NH2htau showed a slightly higher RG than that expected 
for a Gaussian chain, being consistent with the theoretical 
values within three standard errors.
An independent experimental approach to probe 
the flexible nature of the two peptides was obtained 
by comparing the measured RG with the average 
hydrodynamic radius RH [107, 108]. In view of these 
considerations, we measured the hydrodynamic radius 
of NH2htau and its reverse sequence by dynamic 
light scattering (DLS), at the same temperature and 
concentration conditions used in SAXS experiment. In 
Figure 7 we report the number-weighted hydrodynamic 
radius distributions (PN (r) ) of NH2htau (Figure 7g) and 
its reverse sequence (Figure 7h) which were computed 
by averaging a few hundreds of independent PN(r) 
functions. As shown (Figure 7g-7h), distributions were 
monodisperse confirming that the two peptides were of 
high purity and did not contain significant amounts of 
aggregates. An average number-weighted hydrodynamic 
radius (RH )N = 0.95±0.05 nm (eq. 4) and (RH )N = 
0.94±0.05 nm were measured for NH2htau and its reverse 
sequence, respectively. The stability of the two peptides 
was also assessed by monitoring (RH )N over a time of 12 
hours (Figure 7g-7h lower panels). Interestingly and in 
agreement with data shown in figure 1F, (RH )N remained 
constant during 12 hr incubation confirming thus that the 
large part of species in solution was in monomeric form.
A RG/RH ratio of 1.4±0.1 and 1.3±0.1 was obtained 
for NH2htau and its reverse sequence, respectively. As 
reported, these values were consistent with the value 
for an ideal Gaussian chain as expected for a highly 
denaturated protein or an intrinsically disordered protein 
in their Θ-state [107]. At the Θ-point*, chain-chain 
and chain-solvent interactions balanced each other 
such that the polymer was at a critical point, at which 
the thermodynamic phase boundaries disappeared. 
Collectively, these biophysical data further corroborate the 
highly flexible nature of the two peptides and are in close 
agreement with our CD experiments showing that the only 
structure detected in a wide pH range (pH 4-11) is random 
coil (Figure 1A).
To gain better insights into the overall structure of 
the two analyzed peptides, we fitted their experimental 
curves by using the Ensemble Optimization Methods 
(EOM) implemented in the software package ATSAS [92, 
93, 94, 95], which has been widely used to characterize 
many intrinsically disordered proteins, including the full 
length tau and its truncated forms [95, 97, 98, 99] and 
the neurotoxic Aβ 1-42 peptide [102]. The EOM method 
-starting from the aminoacidic sequence- generates a pool 
of models spanning the entire chain’s conformational 
space and then it selects from that pool -by an iterative 
genetic algorithm- the most probable ensemble of 
conformations which best fit the experimental data. The 
RG distributions of the starting pool of conformations 
(gray shaded curve) as well the selected ensemble (open 
square curve) for both NH2htau and its reverse sequence 
peptide are reported in Figure 8A (a-b, respectively). As 
shown, the selected ensembles matched the experimental 
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Figure 7: NH2htau is more extended than its reverse counterpart, hinting at different conformational flexibility. From 
top to bottom of the panel are reported: scattering profiles of NH2htau  (a) and its reverse sequence (b) and the red continuous lines 
indicate the EOM fit of the experimental data; Kratky plots of the two peptides (c,d for NH2htau  and its reverse control sequence, 
respectively); Guinier plot of the two peptides (e,f for NH2htau (a) and its reverse sequence, respectively); Number-weighted hydrodynamic 
radius distributions PN(r) (g,h for NH2htau  and its reverse control sequence, respectively); time evolution of the average number-weighted 
hydrodynamic radius (lower panels of fig g-h for NH2htau  and its reverse sequence, respectively). 
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curves (Figure 7a-7b; continuous red lines). Notably, 
in both cases, the selected ensembles did not span the 
entire available conformational space but only two well-
defined regions peaked around 1 and 1.5 nm, a behavior 
which was confirmed by generating four independent 
starting pools of different numerosity (Supplementary 
Figure 5). The selected ensembles clearly demonstrated 
that the reverse sequence peptide had a higher tendency 
to populate more compacted conformational states in 
comparison to NH2htau (Figure 8A a-b) and, relevantly, 
this propensity was consistent with the higher RG value 
of NH2htau obtained in Figure 7e-7f. A quantitative 
estimation of this trend can be provided by the A1, 5/A1 
ratio, a parameter which was obtained by dividing the area 
of the peak at high RG by that of the peak at low RG value. 
To this point, we measured a value of A1, 5/A1 = 3.2±0.2 
for NH2htau- and of A1, 5/A1 = 1.5±0.2 for its reverse 
counterpart (errors correspond to the weighted standard 
deviation calculated over the four different ensembles 
reported in Supplementary Figure 5). Importantly, the A1, 
5/A1 ratio was found to be significantly different between 
the two analyzed peptides, further supporting the different 
sampling of the phase space which may underlie their 
different biological in vitro effect. Remarkably, it has been 
largely accepted that the pathogenic role of unstructured 
proteins and peptides cannot be related to misfolding 
of given fixed 3D structures, as in the case of globular 
protein, but it is more likely to be strictly correlated to 
the their different capability to fluctuate among different 
conformations which can be significantly altered in 
pathological conditions [43] .
Finally, Figure 8B displays four contact maps (Cα-
Cα distance expressed in Ångström between all pairs of 
residues) of four highly probable conformations, namely: 
a highly probable NH2htau/reverse sequence conformation 
extracted from the peak at low RG values (Figure 8B a-c) 
and high RG values (Figure 8B b-d). A cut-off distance 
of 14 Å was used in these analyses. In Figure 8B a-c, 
we highlighted the occurrence of a long-range contact 
between the region entailing residues 15−19 and the region 
entailing residues 1−5. Furthermore, in the figure insets, a 
snapshot of the corresponding configuration is reported. 
It is worth stressing here that these conformers are not 
meant to provide a statistically significant description of 
the overall conformations of peptide. Conversely, they 
provide an idea of what might be the shape of a compacted 
and an extended conformer.
Altogether and in agreement with CD spectra and 
ThT fluorescence intensity measurements (Figure 1A-1B-
1C-1D-1E), our SAXS analyses confirm that NH2htau 
clearly displays a disordered and monodispersed nature 
under the current experimental conditions. Furthermore, 
Figure 8: Ensembles of Structures Populated by NH2htau in aqueous solution differ from those by its reverse sequence. 
A. EOM starting pool of conformations (gray shaded curves) and selected ensembles (filled square) for NH2htau (a) and its reverse 
counterpart (b). B. contact maps (Cα–Cα distance between all pairs of residues) of four highly probable conformations, namely: a highly 
probable NH2htau/reverse sequence conformation extracted from the peak at low RG values (a-c) and high RG value (b-d). Distances 
between different residues are expressed in Å (a cut-off distance at 14 Å was used). In the figure insets, a snapshot of the corresponding 
configuration is reported.
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these results demonstrate that -in contrast to its reverse 
sequence counterpart- the NH2htau is more prone to 
adopt a specific subsets of “open” conformations - likely 
by exposing important surface residues essential for its 
functional in vivo interaction with specific biological 
partners- which might account for their selective and 
divergent biological effects. Finally, the present data will 
be in aid of future immunotherapeutic interventions [21] 
providing new structural information on the 18-residue 
domain located in N-terminal projection of human tau 
(26-44epitope) which is the minimal biologically active 
moiety of longer secreted 20-22kDa pathologic peptide 
[27, 34] . 
DISCUSSION
Truncation at N-terminal domain of tau plays an 
important role in both neurodegeneration and cognitive 
decline occurring in all brain human tauopathies, 
including the most prevalent Alzheimer’s disease (AD) 
[109]. Tau cleavage has been largely accepted to critically 
contribute to pathogenesis and progression of these 
devastating disorders not only by promoting misfolding /
aggregation of protein but also by releasing soluble toxic 
fragments which induce neurodegeneration in a way 
independent of aggregation [110). Considered that: (i) a 
better understanding of early, asymptomatic and possible 
reversible states in progression of neuropathology of these 
illnesses could help to plan preventive and then more 
effective disease-modifying therapeutic strategies [111]; 
(ii) the extension of tau neuropathology more closely 
correlates with dementia status, being a better predictor 
of cognitive performance than Aβ deposition in any 
region of the brain [112]; (iii) immunotherapy-based in 
vivo Aβ reduction has been proved to have only a limited 
success [4, 5] it has been suggested that a greater clinical 
efficacy may be achieved by clearing extracellular, soluble 
toxic tau species in the earlier stages of the disease when 
cognitive impairments is still not evident [5]. In this 
regards, passive immunization targeting the N-terminally 
truncated forms of tau is being currently pursued in 
phase I clinical trials [113] based on the findings that 
multiple fragments containing NH2/mid-region of human 
protein -but not its C-terminally cleaved and full length 
isoform(s)- are mostly detected in CSF from AD patients 
[9, 10, 11, 12] and in conditioned media from AD patient-
derived induced pluripotent stem cells (iPSC) cortical 
neurons [13, 14]. 
Here we show that low, sublethal doses of soluble 
and extracellular-added human NH2tau 26-44 fragment 
(i.e.NH2htau) - which is the minimal biologically 
active moiety of neurotoxic 20-22kDa parental peptide 
accumulating in vivo in AD presynaptic terminals and 
secreted into extracellular parenchyma [24, 25, 28, 33, 
34]- are able to impact on normal synaptic function(s) by 
acutely interfering with depolarization-evoked glutamate 
release from purified hippocampal nerve terminals. 
Significant reduction in presynaptic neurotransmitter 
exocytosis is paralleled by local alteration in peak 
amplitude and kinetic parameters of Ca2+ transients 
which concomitantly take place in K+-stimulated 
isolated synaptosomal preparations. Biochemical and 
morphological changes, such as selective reduction in 
presynaptic proteins along with marked neuritic dystrophy 
and loss of synaptic mitochondria which are classically 
detected in the pre-symptomatic neuropathologic stages 
of human tauopathies, are found in in vitro neuronal 
cultures only after chronic incubation with extracellular 
NH2htau and prior to overt cell death. The specificity 
of these results is further supported by the lack of any 
significant biological effect contextually shown by 
application of reverse peptide which behaves as inactive 
control in all the above-summarized analyses, likely due 
to its poor conformational flexibility which makes it 
unable to dynamically perturb lipid membranes in contrast 
to NH2htau. This evidence is biologically relevant to 
human pathology and important in terms of translational 
outcome, in view the fact that a population of NH2-
terminal truncated fragments of tau protein -including 
our peptide [21, 27, 28]- is mainly present in CSF from 
human AD patients and secreted from cryopreserved 
synaptosomes following depolarizing stimulus [9, 28]. 
Importantly, in support of a recent report elucidating 
the beneficial role sustained by the immunodepletion of 
N-terminal projection of tau (residues 6-18) in improving 
memory deficits in 3XTgAD mice [20], these results 
hopefully prospect that passive immunization with 
the our newly-developed 12A12 monoclonal antibody 
Table 2: Peptides concentration as measured by using the Guinier’s approximation (first column); gyration radius RG 
(second column) and hydrodynamic radius (third column) as measured by SAXS and DLS; RG/RH  ratio obtained by 
columns 2 and 3 (4th column); Calculated RG value for an ideal Gaussian Chain according to eq. 1 (5th coulmn).  RG 
value computed by using the Ensable Optimization Method EOM (6th coulmn); A1.5/A1 values obtained by dividing the area 








ν RG (nm) EOM A0.155/A0.97
NH2htau 2.5±0.1 1.32±0.03 0.95±0.05 1.4±0.1 RG=1.18±0.06 1.31±0.05 3.1±0.2
Reverse 2.4±0.1 1.23±0.03 0.94±0.05 1.3±0.1 RG=1.18±0.06 1.21±0.05 1.5±0.2
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targeting the N-terminal sequence of human protein 
encompassing the 26-44 aminoacidic stretch could 
actually represent an effective therapeutic opportunity for 
AD and other tauopathies. In addition, the observation 
that the primary and earlier target of action of pathogenic 
extracellular NH2htau appears to be the functional release 
of neurotransmitter from nerve terminal ends -which is 
followed by delayed mechanisms of cell degeneration- 
are in agreement with previous observations reporting 
that synaptic impairment precedes the tardive cell loss 
in patients and in experimental models of tauopathies, 
including AD [114]. Finally, the findings that pathogenetic 
NH2-truncated tau is capable of negatively affecting the 
presynaptic glutamate release from isolated synaptosomes 
in Ca2+ -dependent manner are also in line with previous 
electrophysiological, behavioral, biochemical and 
morphological evidence showing that mutated htau -in 
addition to its classical postsynaptic actions [17] and 
prior to frank neuronal loss- is also able to induce an early 
synaptic dysfunction by means of presynaptic mechanisms 
including changes in Ca2+ homeostasis, altered probability 
of neurotransmitter release, ultrastructural abnormalities 
and reduced expression of presynaptic markers [115, 116, 
117, 118, 119, 120, 121]. 
Extracellular NH2-truncated tau disrupts Ca
2+- 
dependent glutamate release at presynaptic 
terminals: potential pathomechanism(s) and 
relevance to neurodegeneration
A causal association between intracellular 
accumulation of pathological tau species and dysregulation 
of calcium homeostasis in the brains of AD patients and 
in cellular and animal models has been already described 
[55, 56]. As shown by functional analyses carried out on 
purified synaptosomal preparations (Figure 3-4), in the 
present study we report that the secreted and pathologically 
AD-relevant NH2htau fragment from the extracellular 
milieu limits the depolarization-evoked glutamate release 
in a potent (at nanomolar concentrations) and rapid 
manner (within few minutes), likely acting on regulation 
of intracellular Ca2+ dynamics at the level of stimulus-
exocytosis cascade. To this point, although several 
mechanisms should be taken into account, we favor the 
hypothesis of an indirect effect on intrinsic viscosity of 
lipid bilayers of neuronal plasma membrane leading to 
a plausible partitioning/diffusion of the (Cav)2.1 and 
(Cav)2.2 voltage-gated calcium channels (VDDC, P/Qtype 
and N-type respectively) which are known to be located 
into lipid-rafts and responsible for coupling of neuronal 
depolarization with neurotransmitter release at the level 
of presynaptic terminals [122]. In this regard, pathological 
tau has also been reported to accumulate within these cell-
surface detergent-resistant microdomains of the plasma 
membrane in aging Tg2576 transgenic mice and AD 
brains [123] and the N-terminal projection domain of tau 
protein associates to lipid-rich rafts of plasma membrane 
in a phosphorylation-dependent manner [41]. Besides, our 
biochemical and biophysical results from kinetic studies 
of evoked Ca2+transient along with Western blotting and 
DSC analyses (Figure 2-3-4-5) further support the above 
observations demonstrating that: (i) the dose-dependent 
impairment of glutamate exocytosis induced by NH2htau 
attached to surface of isolated nerve endings occurs 
upstream of Ca2+ dynamics out of the action mechanism 
of neurotransmitter release induced by external high 
[KCl] which is known to involve only the depolarization-
evoked activation of voltage-dependent Ca2+ channels 
[57, 59] and not of other ion-channels modulating the 
synaptic terminal excitability; (ii) treatment of neuronal 
cultures with NH2htau does not induce per se up to 48h 
any significant alteration in the protein expression level 
of some components of cytoskeleton and/or of release 
machinery which is relevantly involved in controlling the 
excitatory neurotransmission, excluding the possibility 
of a direct effect downstream of Ca2+ entry on synaptic 
vesicle trafficking/ exocytosis apparatus and on axonal 
transport; (iii) upon its prompt interaction with the 
surface of biomembrane-mimicking environments, the 
external application of NH2htau gives rise to a profound 
phase segregation of lipid bilayer leading to a selective 
enrichment in more rigid, raft-like microdomains which 
are largely accepted to be the cellular sites where 
functional assembly of SNARE (soluble N-ethyl-
maleimide-sensitive fusion protein attachment protein 
receptor) components of vesicular exocytotic machinery 
with presynaptic P/Q calcium channels occurs [122]. 
In addition, our preliminary data (not shown) from 
microscopy visualization of membrane fluidity by means 
of 2-Dimethylamino-6-lauroylnaphthalene (Laurdan) 
fluorescence points to a significant perturbation in lipids 
packing upon short-term exposure of neuronal cultures 
to NH2htau but not to its reverse control sequence. 
Interestingly, it has been reported that α-synuclein 
associates with lipid-rafts microdomains [52] in a 
similar way of N-terminal end of tau [16] and that, when 
extracellular-applied in its monomeric form, is able 
to early perturb calcium homeostasis by affecting the 
portioning of several cell surface-associated proteins [124, 
125]. Therefore consistent with our immunofluorescence 
stainings (Figure 2), it would be reasonable to hypothesize 
that secreted NH2htau might change the membrane 
fluidity/composition upon its prompt interaction with 
presynaptic boutons and alter thus the distribution and/
or insertion of Ca2+ channels into sorting /signaling lipid 
platforms as well as the association of these channels 
with appropriate effector proteins, thus inhibiting their 
activities [126]. Of note, biophysical parameters (bending, 
fluidity and thickness) underlying the reciprocal spatial 
organization between lipids membranes and surface-
associated proteins have been largely accepted to actively 
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participate in presynaptic functions and to drive the 
neurotransmitter release in neurons via regulation of 
proteins trafficking and activity. In line with our DSC 
analyses, previous studies have also proved that one of 
the initial steps in neurotoxic biological effects evoked by 
rather low concentrations of Aβ stems from a “membrane-
disordering effect” caused by alteration in acylchain 
layer and, thus, in fluidity of cell membranes [127]. 
Additional studies are required to test this possibility 
and further experiments are under current investigation 
to better address the presynaptic pathway(s) underlying 
the membrane-mediated actions of NH2htau in neurons. 
In relation to the presynaptic Ca2+-dependent coupling 
between stimulus and neurotransmitter secretion of interest 
is the fact that, as shown in our correlational studies of 
Ca2+ imaging and radioactivity-based measures of [3H]
D-aspartate release, the peak of K+-evoked elevation 
in Ca2+ current turns out to be somewhat higher and to 
decline to a stable plateau more quickly in hippocampal 
isolated nerve terminals exposed to NH2htau than in other 
two experimental group (reverse- and untreated controls), 
resulting in overall decrease of glutamate release (compare 
Figure 3 to Figure 4). To this point, it’s worth stressing that 
the strength of glutamatergic synapses depends on both the 
peak and the kinetic of [Ca2+] transient (duration) near its 
sensors. It has been largely accepted that depolarization 
of synaptosomes by elevated KCl initiates a rapid “spike” 
of Ca2+ current within 1-2 s of stimulation followed by a 
more extensive slow plateau. The K+ -evoked secretion 
of glutamate neurotransmitter from synaptic terminals 
does not correlate with the increase in [Ca2+] bulk but 
occurs for the large part during its late recover to a 
plateau, undergoing a biphasic release which may reflect 
a dual localization of releasable vesicles at the active 
zone and in the cytoplasm [128]. Therefore, we argue 
that greater but shorter signal of activity-dependent Ca2+ 
transient could account for pathophysiological deficits 
induced by extracellular NH2htau on neurotransmission 
at the presynaptic level (Figure 3J-3K). Furthermore our 
findings on acute and potent inhibitory action exerted by 
pathogenetic NH2-truncated tau on glutamate release from 
isolated synaptosomes (Figure 4I) are also in line with the 
emerging concept that the unbalance in network activity 
occurring in vivo in prodromal AD subjects is more 
likely to reflect a decreased capacity of cerebral neurons 
to cope with existing glutamate level that becomes 
toxic at concentration that normally shows no harmful 
effect. Relevantly, magnetic resonance spectroscopy has 
revealed a significantly lower level of glutamate in AD 
brains compared to healthy controls and patients with mild 
cognitive impairment [129]. In line, soluble pathological 
tau species have been recently proved to be able to 
change the neuronal electrical properties in the rTg4510 
(mutation P301L) mouse model of tauopathy, provoking 
a diminution in global neuronal activity with slower 
spontaneous oscillations and a reduced firing rates, prior 
to significant cell death or synapse loss [130]. 
Pathological molecular/structural determinants at 
N-terminal extremity of human tau protein: novel 
opportunities for tau-based immunotherapy in 
AD and other tauopathies
In addition to aberrant calcium homeostasis 
and imbalance in neurotransmitter release, selective 
and regional loss of presynaptic terminals, neurite 
retraction, breakdown of microtubules, prominent loss of 
mitochondria which specifically reside at nerve endings are 
also discernable in transgenic animal model of tauopathy 
and in AD patients by sensitizing neurons to “dying 
back” prior to overt cell death [30, 80, 81, 131, 132, 133]. 
Consistently, our in vitro biochemical data from Western 
blotting and immunofluorescence analyses (Figure 
5-6-Supplementary Figure 4) show a dose-dependent 
diminution in selective markers involved in trafficking/
priming of presynaptic vesicles along with a pronounced 
degeneration of neuronal processes and reduction in 
mitochondrial density only after 48h incubation time 
with low doses of NH2htau, in absence of any significant 
global change in cell viability (Supplementary Figure 3) 
which conversely appeared evident later on (72-96h). 
These findings are relevant because synaptotoxicity, 
axonopathy and mitochondrial abnormalities induced 
in vitro by chronic and sublethal exposure of mature 
hippocampal primary neurons to NH2htau recapitulate 
a few important in vivo biochemical and morphological 
changes that closely resemble the pre-symptomatic 
neuropathologic stages of human tauopathies. To the point 
and in line with our in vivo previous results [26], recent 
findings have endorsed a crucial role of tau dysfunction 
in affecting biology and density of mitochondria located 
at terminal ends (i.e. synaptic mitochondria) [89]. 
Proteomic analyses have also shown that presynaptic 
compartment, along with a significant impairment in 
dynamic stability of microtubules and reduction in number 
of synaptic vesicles, are preferentially deregulated in vivo 
into transgenic mice expressing another toxic human 
truncated tau fragment (aa 151-391) [134]. In addition, 
the A152T tau mutation -a tauopathies risk factor which 
lies within the N-terminal projection region of protein 
not involved in interaction with microtubules - has been 
recently shown to perturb presynaptic neurotransmission 
and mitochondrial distribution in C.elegans worms, in 
absence of any accumulation of insoluble intracellular 
aggregates [135]. Therefore and in a similar way of 
extracellular-added monomeric Aβ 1-42 whose continuous 
exposure (i.e. without replacing the culture media up 
to 72-96h) to cortical primary neurons is required to 
achieve maximal neurotoxicity due to its sequential 
binding to membranes, a threshold level of membrane-
bound NH2htau could be needed to trigger a full-blown 
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neuronal cell death. Alternatively, neurotoxicity initiated 
by binding of extracellular-added monomeric NH2htau to 
membranes could depend on the activation of long-term 
intracellular signaling transduction pathways which affect 
one or more second messengers controlling, directly or 
indirectly, the neuronal bioenergetics, cytoarchitecture 
and synapses integrity. Finally and in agreement with our 
DSC kinetic analyses (Figure 2) displaying that NH2htau is 
able to interact with the deep hydrocarbon region of lipid 
bilayer only after longer incubation times (48-72h), it’s 
also hypothesizable that -following its initial adsorption 
on the external side of plasma membrane- a residual 
amount of this peptide could be later internalized and 
even undergo an intracellular misfolding which, in turn, 
causes the delayed loss of synapses, neurite retraction 
and mitochondrial deficit. Consistent with these findings, 
monomeric exogenous tau has been demonstrated to 
be up-taken by neurons [136, 137] and aggregate into 
endosomes [136]. Interestingly, high intracellular levels 
of pathogenetic NH2htau are able to interfere with the 
mitochondrial biology leading to drop of energy (ATP) and 
eventually to neuronal death, as we previously reported 
[138]. Furthermore, quantitative mass spectrometry 
following co-immunoprecipitation with an antibody 
just encompassing the extreme N-terminal domain (27-
40aa) of tau protein have also revealed that numerous 
pre-synaptic proteins involved in vesicle docking/fusion 
-together with a large number of mitochondrial markers- 
are selectively pulled-down from mice brains [139] . 
Concerning a direct role of self-aggregation in 
affecting synaptic function, it’s also worth mentioning 
that the oligomerization process of full length or truncated 
tau species is not essential for internalization, secretion 
and propagation [13, 22, 62, 136, 140] and that truncation 
can cause degeneration independently of its aggregation 
[110]. Our observations from CD spectra, ThT-binding 
fluorescence intensity measurements and SAXS analysis 
confirm the unstructured/flexible and monodisperse 
nature of NH2htau in water environment under current 
experimental conditions along with EOM study unraveling 
its intrinsic propensity to adopt specific conformational 
ensembles which might account for its potent in vitro 
biological effects (Figure 1, 7, 8). Therefore, although 
we cannot completely rule out that NH2htau can undergo 
temporary structural changes [35] as well as membrane-
induced conformational transitions [42, 43] facilitating its 
folding/clustering in amorphous and/or partially structured 
aggregates over longer periods of times, our findings 
clearly demonstrate that this N-terminal tau peptide adopts 
a pathological conformation being certainly in vitro toxic 
when extracellular-added to neurons in its prevailing 
monomeric form. 
It’s worth pointing out that , in the present work 
we used concentrations for NH2htau ranging from 1nM 
to 1µM which are within the physiological range of 
unbound/free tau [61, 65] and within the range previously 
used by other authors in assessing the extracellular role of 
full length tau (62) or its C-terminal [141] and N-terminal 
[13] active fragments on cell lines and primary neurons 
respectively. Furthermore, it’s noteworthy that: (i) the 
activity-dependent secretion of full length tau may 
occur through synaptic transmission [142] and (ii) the 
pre-synaptic release of longer 20-22kDa tau fragment 
occurs following K+ depolarization of AD terminal ends 
[28]. Therefore, although the amount of extracellular 
NH2htau required to affect synaptic functions is higher 
than the diffusive levels of tau found in AD patient 
CSF or in the conditioned media from neuronal cultures 
and in interstitial fluids, it’s more likely to assume 
that the secretion of soluble tau species through a 
synaptic mechanism would necessarily generate local 
concentrations at the release site, and likely site of action, 
which are significantly higher than its circulating levels 
[13]. 
Regarding the observation that no significant effect 
on basal synaptic exocytosis was found out in neurons 
upon treatment with subtoxic doses of extracellular 
NH2htau, compelling evidence has proved that the stimuls-
independent discharge at the level of the release machinery 
and the action potential-triggered neurotransmitter release: 
(i) rely on independent neuronal signal transduction 
pathways and on divergent presynaptic machineries and/
or postsynaptic targets that may even operate in a spatially 
segregated manner; (ii) are not linked with respect to their 
relative activities because modulations of spontaneous 
release are not always accompanied by corresponding 
changes in evoked exocytosis. Therefore, following 
binding to plasma membrane and consequent alteration in 
the lipid bilayer fluidity as we detected by DSC (Figure 
2), it’s conceivable that extracellular NH2htau might 
perturbate the localization and, then, the activation of 
one or more membrane-associated proteins which are 
selectivity associated to regulated neurosecretion. The 
specific effect induced by extracellular NH2htau on the 
movement/distribution of distinct membrane-associated 
proteins in lipid rafts and, then, on the differential 
regulation of evoked versus spontaneous neurotransmitter 
release, is possible to be dependent on the different 
strength of association of proteins with membrane bilayer, 
or on the differential role of lipid raft elements in the 
maintenance of proteins cluster and in the confinement of 
distinct proteins in their specific site of localization [125].
Finally it’s also noteworthy that, although the 
extracellular NH2tau 26-44 fragment (i.e.NH2htau) only 
comprises 19 amino acid sequence of over 400 amino 
acids included in full length tau sequence, it represents the 
minimal biologically active moiety of longer 20-22kDa 
parental peptide [27, 33, 34]. Therefore, given that (i) 
molecular characterization of identity of the extracellular 
toxic tau species is mandatory to design a best-targeted 
and more effective immunotherapy relying on the specific, 
epitope-directed and antibody-mediated depletion [4, 
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5]; (ii) the NH2 26-44aa is critical aminoacidic stretch 
representing the biologically active moiety of 20-22kDa 
AD-relevant secreted NH2-truncated tau forms [24, 27, 
34], our findings can be particularly relevant for tau 
physiopathology in the field of AD and other tauopathies, 
helping to design more beneficial tau-directed and disease-
modifying in vivo curative approaches. To this regard, it’s 
worth noting that passive immunotherapy with HJ 8.5 
targeting the N-terminal projection domain of human tau 
(residues 25-30) has proved to be succesful in inhibiting 
the transcellular propagation of tau and improving 
cognitive deficits in P301S tau transgenic mice [143]. In 
addition, based on the encouraging in vivo results from 
tauopathy animal models [20, 143, 144], clinical trials 
with a set of monoclonal tau antibodies binding to and 
clearing the extracellular and/or intracellular pathological 
species including the extreme N-terminal region of human 
protein are currently in progress [5].
CONCLUDING REMARKS
In summary, the present investigation not only 
confirms and extends the notion that extracellular tau 
is per se harmful for neurons [13, 23, 62] but also 
opens novel and potentially more effective therapeutic 
opportunities aimed at preventing the early impairment 
in synaptic plasticity and memory caused by one of 
the actually secreted [21, 27, 28] and, consequently, 
pathologically relevant N-terminal truncated species in 
human tauopathies. 
MATERIALS AND METHODS
 Chemicals and antibodies
Brain Total Lipid Extract (TLBE), 1, 2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC) and 1, 
2-dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS) 
1, 2-palmitoyl-oleoyl-sn-glycero-3-phosphocholine 
(POPC) and 1, 2-palmitoyl-oleoyl-sn-glycero-3-
phosphoserine (POPS) were purchased from Avanti Polar 
Inc. (Alabaster, AL). All N-fluorenylmethoxycarbonyl 
(Fmoc)-protected amino acids, Fmoc-NH-(PEG)11-
COOH, 2-(1-H-benzotriazole-1-yl)-1, 1, 3, 
3-tetramethyluronium tatrafluoroborate (TBTU), and 
NovaSyn TGR resin were obtained from Novabiochem 
(Switzerland); N, N-diisopropyl-ethylamine (DIEA), 
N-hydroxybenzotriazole (HOBt), DMF (peptide-synthesis-
grade), triisopropylsilane (TIS), trifluoroacetic acid (TFA), 
Thioflavin T (ThT), Sodium dodecyl sulfate (SDS), 2, 2, 
2-Trifluoroethanol (TFE), N, N-diisopropylethylamine 
(DIEA), N, N-dimethylformamide, piperidine, 
triisopropylsilane (TIS), trifluoroacetic acid (TFA) and 
all salts used for buffer preparation were purchased from 
Sigma-Aldrich (St.Louis, MO) with a purity of 99%. 
SynaptoRed C2 (FM4-64) 70021, SynaptoGreen C4 
(FM1-43) 70022 were from Biotium (Hayward, CA); 
Calcium Indicator (Fluo-3AM) F1242 was from Thermo 
Fisher Scientific (Massachusetts, MA).
The following antibodies were used: β-III tubulin 
antibody rabbit ab18207 Abcam; β-III tubulin antibody 
mouse (clone 2G10) T8578 Sigma-Aldrich; β-actin 
mouse S3062 Sigma-Aldrich; Synapsin I antibody rabbit 
AB1543P Millipore Corporation; PSD95 antibody (clone 
7E3-1B8) mouse MAB1598 Millipore; PSD95antibody 
(clone: 6G6-1C9) mouse ADI-VAM-PS002 EnzoLife 
Science; synaptophysin antibody mouse sc-17750 Santa 
Cruz; Calnexin antibody ( clone C-20) goat sc-6465 Santa 
Cruz ; MAP-2 antibody mouse MAB3418 Millipore; 
dynamin antibody mouse BD Transduction Laboraories 
610246; GAPDH antibody (clone GAPDH-71.1) 
G8795Sigma-Aldrich ; SNAP25 antibody mouse (clone 
SMI81) Biolegend 836301; SV2A antibody (clone E-8) 
mouse sc-376234 Santa Cruz; α-synuclein antibody 
(clone 42) mouse 610786 BD Transduction Laboratories; 
α-synuclein antibody rabbit S3062 Sigma-Aldrich; 
synaptotagmin antibody (clone ASV48) mouse SYA-
148 Stressgen; anti complex IV subunit I MTCO1 (clone 
1D6E1A8) ab14705 MitoSciences; NMDAζ1 antibody 
(C-20) goat sc-1467 Santa Cruz; vGLUT1antibody rabbit 
135 302 Synaptic System ; Anti- caspase 3cleaved (active) 
form antibody rabbit AB3623 Millipore; golgin 97 (E-16) 
antibody goat sc-74632 Santa Cruz. 
 Synthesis, purification, labeling and preparation of tau 
peptides
NH2 htau 26-44 and its reverse sequence control 
peptide were synthesized and purified using reverse-
phase HPLC (D.B.A., Milan, Italy). Peptides mass 
and purity (>99%) were confirmed by reverse-phase 
HPLC and electrospray/ion trap mass spectrometry. A 
lyophilized powder of peptides was dissolved in at a stock 
concentration of 1 mM by brief stirring. Aliquots were 
stored at -80°C prior to use. The working solution was 
diluted with PBS or ultrapure water at a concentration of 
50 μM at 4°C and used immediately. Peptide preparations 
were analyzed by Sypro Ruby protein staining and SDS-
PAGE Western blot for each experiment. 
NH2 htau 26-44 :NH2 QGGYTMHQDQEGDTD 
AGLK- COOH 
Reverse sequence control peptide :NH2 
KLGADTDGEQDQHM TYGGQ- COOH
FITC- conjugated NH2htau 26-44 was synthesized 
and purified (>99%) using reverse-phase HPLC 
(Biosynthesis, U.S.A.). 
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Generation of the N-terminal tau 12A12 antibody 
(26-36aa)
 Affinity-purified mouse monoclonal antibody 
directed against the extreme N-terminal 26-36 aa of 
human tau protein (12A12) was produced, purified and 
characterized by Monoclonal Antibodies Core Facility 
(MACF) at EMBL- Monterotondo, Rome, Italy (Dott.
Alan Sawyer). 
12A12 was generated by immunizing mice with 
a peptide of amino acids 26-36 aa of hT40 (D25(NH2 
QGGYTMHQDQ-COOH epitopes). The specificity of this 
mAb (IgG isotype) was verified by Western blot analysis 
(Figure 1F-1G) and enzyme-linked immunosorbent assay 
(ELISA) test (95% sensitivity and 90% specificity). 
Preparation of artificial biomembrane model 
system
We used large unilamellar vesicles (LUVs) 
composed of TLBE or DMPC/DMPS (7/3 molar 
ratio). Model membranes were prepared as described 
elsewhere [47]. Briefly, aliquots of lipid stock solutions in 
chloroform were dried by using a stream of dry nitrogen 
gas and evaporated under high vacuum to dryness in a 
round-bottomed flask. To obtain multilamellar vesicles 
(MLVs), the resulting lipid film was hydrated with an 
appropriate amount of phosphate buffer (10 mM buffer, 
100 mM NaCl, pH = 7.4) and dispersed by vigorous 
stirring in a water bath. LUVs were obtained by extruding 
MLVs through polycarbonate filters (pore size = 100 
nm, Nuclepore, Pleasanton, CA) mounted in a mini-
extruder (Avestin, Ottawa, ON, Canada) fitted with two 
0.5 ml Hamilton gastight syringes (Hamilton, Reno, NV). 
Samples were typically subjected to 23 passes through 
two filters in tandem and as recommended elsewhere. 
An odd number of passages were performed to avoid 
contamination of the sample by vesicles that might not 
have passed through the filter.
Circular dichroism
The CD spectra were obtained at 25°C (if not 
differently specified) under a constant flow of N2 
on a Jasco J-810 spectropolarimeter equipped with a 
Peltier thermoelectric type temperature control system. 
Experimental measurements were conducted in several 
condition, using 1 cm path length cuvettes. The CD 
measurements were carried out under a variety of 
experimental conditions, including different pH levels and 
membrane-mimicking enviroments (i.e negatively charged 
SDS, anionic-zwitterionic POPC/POPS LUV and water/
TFE mixtures). The CD spectra were recorded in the UV 
region (190-260 nm) with peptide concentration of 10 µM. 
CD intensities are expressed as molecular ellipticity. 
ThT assay
The kinetics of amyloid fiber formation were 
measured using the increase of fluorescence emission 
upon binding of commonly used amyloid specific dye, 
thioflavine T (ThT). Samples were prepared by adding 5 
µL stock solution of tau26-44 or tau44-26 to 100 µL of 
10 mM phosphate buffer solution pH 7.4, 100 mM NaCl 
or to 100 µL of a TLBE 7/3 LUVs solution, containing 
60 µM ThT (final peptides concentration was 20.0 µM). 
Experiments were carried out in Corning 96 well non 
binding surface plates. Time traces were recorded using 
a Varioskan plate reader (λecc 440 nm, λem 482 nm) at 
37 °C, shaking samples for 10 seconds before each read. 
Time traces are the average of three measurements.
Differential scanning calorimentry (DSC)
The interaction of NH2htau and reverse control 
peptide with model membranes was tested by performing 
DSC experiments. Samples were prepared by adding the 
proper amount of a stock solution (800 µM) of both tau 
peptides to 1 ml of LUV DMPC/DMPS 7/3 200 µM. The 
final peptides concentration was 20 µM. Five independent 
samples were prepared in order to perform experiments 
every 24 hours up to 72 hours . All the experiments were 
collected from 10 to 40 °C, 1 °C/min scanning rate at the 
pressure of 3 atm using a nanoDSC (TA instrument).
Animals
All protocols involving animals were performed 
in accordance with the guidelines established by the 
European Communities Council (Directive 2010/63/EU 
of 22 September 2010). Experiments involving animals 
were performed in accordance with the relevant approved 
guidelines and regulations accepted by the Italian Ministry 
of Health and approved by the Ethical Committee on 
animal experiments of EBRI “Rita Levi-Montalcini” 
Foundation (Rome, Italy).
Synaptosomes preparation
Mouse hippocampal purified synaptosomes were 
prepared by homogenizing tissue in 10 volumes of 0.32 
M sucrose, buffered to pH 7.4 with Tris-(hydroxymethyl)-
amino methane [Tris, final concentration (f.c.) 0.01 M] 
[75]. The homogenate was centrifuged at 1, 000 x g for 5 
min and the supernatant was stratified on a discontinuous 
Percoll gradient (2%, 6%, 10% and 20% v/v in Tris-
buffered sucrose) and centrifuged at 33, 500 x g for 5 min. 
The layer between 10% and 20% Percoll (synaptosomal 
fraction) was collected and washed by centrifugation. In a 
set of experiments, the tissue was homogenized in buffered 
sucrose containing 1 mM 1, 2-bis-(2-aminophenoxy) 
ethane-N, N, N’, N’, tetra-acetic acid (BAPTA), in order to 
entrap this agent into subsequently isolated synaptosomes 
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[75]. The synaptosomal pellets were resuspended in a 
physiological solution with the following composition 
(mM): NaCl, 140; KCl, 3; MgSO4, 1.2; CaCl2, 1.2; 
NaH2PO4, 1.2; NaHCO3, 5; HEPES, 10; glucose, 10; pH 
7.2-7.4. To ascertain whether fractionated preparations 
were really enriched in synaptic terminals and free of any 
contaminations from neuronal perikarya, Western blotting 
analysis was carried out to check the purity of samples 
by probing with antibodies against the presynaptic protein 
synapthophisin and cytosolic GAPDH, as previously 
reported [27].
Synaptosomal glutamate release
Synaptosomal glutamate release was estimated 
as previously reported [74, 75, 77] . In details, isolated 
hippocampal ending nerves were incubated for 45 min 
at 37°C in a rotary water bath in the presence of [3H]
D-aspartate ([3H]D-ASP; a non-metabolizable analogue 
of glutamate used to label the synaptosomal glutamate-
releasing pools used at final concentration 50 nM). 
Aliquots of synaptosomal suspension (5-10 μg protein) 
were equally distributed on microporous filters placed 
at the bottom of a set of parallel superfusion chambers 
maintained at 37 °C (Superfusion System, Ugo Basile, 
Comerio, Varese, Italy) [74]. Superfusion was then started 
with standard medium at a rate of 0.5 ml/min and continued 
for 48 min. After 39 min of superfusion to equilibrate the 
system, synaptosomes were transiently (90s) exposed to 
high K+ containing medium (12 mM, NaCl substituting 
for an equimolar concentration of KCl), and then fractions 
were collected according to the following scheme: two 
3-min fractions (basal release), one before (t = 36-39 min) 
and one after (t = 45-48 min), a 6-min fraction (t = 39-45 
min; evoked release). When indicated, synaptosomes were 
superfused with medium in which Ca2+ ions were omitted 
to prevent any Ca2+-dependent releasing activity.Collected 
fractions and superfused synaptosomes were measured for 
radioactivity. The amount of radioactivity released into 
each superfusate fraction was expressed as percentage 
of the total radioactivity. The K+-induced overflow was 
estimated by subtracting the neurotransmitter content the 
first and the third fractions collected (basal release, b1 
and b3) from that in the 6-min fraction collected during 
and after the depolarization pulse (evoked release, b2). 
In a set of control experiments performed to evaluate 
the Ca2+-dependency of the induced [3H]d-ASP release, 
the superfusion medium was replaced, starting from t 
= 20 min, with a medium containing 0.1 mM Ca2+ and 
500 μM EGTA. In some experiments, synaptosomes 
were incubated 30 min (15 min before and during [3H]
d-Asp labelling) in the presence of 100 μM 1, 2-bis-(2-
aminophenoxy)-ethane-N, N, N′, N′-tetraacetic acid, 
tetraacetoxymethyl ester (BAPTA-AM).
Vesicles exocytosis FM1-43 or FM4-64 assay
Depolarization-dependent FM1-43 or FM4-
64 destaining was used to measure synaptic vesicle 
fusion events with the plasma membrane on intact 
nerve terminals (i.e., synaptosomes) [59, 71, 72, 73]. 
Isolated synaptosomal fractions from mature rat primary 
hippocampal neurons (15DIV) seeded on coverslips 
were incubated in physiological salt solution (PSS; 
NaCl 140 mM, glucose 11.5 mM, KCl 5.9 mM, MgCl2 
1.4 mM, NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 1.8 
mM, HEPES 10 mM) and then with FM1-43 (50 μM) 
for 2 min, followed by application of high KCl 30 mM 
to intrasynaptically load the fluorescent dye. After 1 
min, synaptic preparations were washed twice to remove 
non-internalized FM1-43 and placed on an incubation 
chamber of a time-lapse system composed by an 
inverted fluorescence microscope (TiE; Nikon, Japan), 
equipped with an incubation chamber (Okolab), a cooled 
CCDcamera (Clara;Andor), a Perfect Focus System 
to avoid z-axis focus fluctuations and a Niss Elements 
imaging software (Nikon). After 1 min a baseline was 
established, synaptoneurosomes were incubated (t = 1) 
with either NH2htau peptide or its reverse sequence control 
(both 1µM) for additional 5 min and then (t = 6) stimulated 
by application of 30mM KCl which we previously stated 
in pilot experiments to be the minimum concentration 
able to induce robust responses in our samples. Video 
recordings were performed with a 40×oil objective (N.A 
1.4) for at least 10 min and 14 bit images were captured 
by 200 ms exposure time every 2 s at room temperature 
(25°C). After fluorescence recordings, one differential 
interference contrast (DIC;Nomarski) image of the field 
was taken for visual inspection of global morphological 
features (data not shown). Video images were analyzed by 
using the Spot module of the ImarisSuite 7.6® software 
(Bitplane A.G., Zurich, Switzerland) by semiautomated 
application of 1.5 μm radius diameter mask on fluorescent 
puncta. The criteria for fluorescence puncta inclusion in 
the data analysis were the spherical shape ranging between 
0.5-1.5 micron and the stimulation-dependent destaining 
response. Destaining time courses were generated by 
normalization of each fluorescence spot trace by using 
the formula Fi/F0 where F0 is the fluorescence before 
stimulus addition (average of 10 time points of the image 
t-stack) and Fi is the fluorescence at each time point. 
Quantification of FM1-43 exocytosis responses was 
accomplished by calculating the average percentage of 
fluorescence loss and a group of control experiments was 
also contextually run to test the specificity of dye loading 
and destaining, as following: (i) incubation in Ca2+-free 
Ethylene Glycol TetraAcetic acid (EGTA)-containing 
medium drastically reduced both the FM1-43 loading 
and inhibited the K+ stimulus-induced dye release; (ii) the 
FM1-43 photobleaching rate was measured in absence of 
the K+ stimulus. To verify whether NH2htau could induce 
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per se synaptic release, we additionally performed a few 
control experiments using the same experimental setting 
conditions with the exception that the NH2htau was 
incubated with the synaptosomes and the KCl stimulus 
was substituted by saline addition.
Intracellular calcium imaging in cultured neurons 
and isolated synaptosomes
Relative changes in the cytosolic Ca2+ concentration 
were measured using the Ca2+ -sensitive fluorescent dye 
indicator Fluo-3 AM. Hippocampal primary neurons 
and isolated hippocampal ending nerves were incubated 
for 45 min in the dark at room temperature with 2 µM 
Fluo-3 AM dissolved in 0.02 % pluronic acid (both from 
Biotium, Hayward, CA) in physiological salt solution 
(PSS; NaCl 140 mM, glucose 11.5 mM, KCl 5.9 mM, 
MgCl2 1.4 mM, NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 
1.8 mM, HEPES 10 mM). To allow for completion of 
Fluo-3 AM de-esterification process, cultures were washed 
and incubated in PSS alone for 10-15 min at 37 °C and 
then visualized and recorded by using a time-lapse system 
mounted on an inverted fluorescence microscope (TiE; 
Nikon, Japan), equipped with: (i) an incubation chamber 
(Okolab, Italy), (ii) a cooled CCD camera (Clara; Andor), 
(iii) filters for Differential Interference Contrast (DIC; 
Nomarski) acquisitions, (iv) Perfect Focus System to avoid 
z-axis focus fluctuations and a (v) Niss Elements imaging 
software (Nikon). Video recordings were performed 
with a 20X objective, for at least 20 min, and 12 bit 
images were captured by 200 ms exposure time every 2 
s at room temperature (25°C). After 1 min a baseline was 
established, neurons were incubated (t = 1) with either 
NH2htau peptide or its reverse sequence control (1µM) for 
additional 5 min and then (t = 6) stimulated by 30 mM KCl 
addition, which we previously verified in pilot experiments 
to be the minimum concentration able to induce robust 
responses on our in vitro cultures. After fluorescence 
recordings, one DIC image of the fluorescence field was 
taken for visual inspection of morphological features. 
Fluorescence intensity changes were calculated as (F-F0)/
F0, where F was the fluorescence intensity measured in 
each frame after stimulation and F0 the basal fluorescence 
level calculated by averaging the intensity values 20 sec 
before the peak. Video images and pixel intensities were 
evaluated afterwards, by using Imaris Suite 7.6® Track 
module (Bitplane A.G., Zurich, Switzerland) and Image 
J 1.4 (imagej.nih.gov/ij/) softwares by applying a 1.5 μm 
radius diameter mask on fluorescent puncta. However, 
some puncta which visually displayed a faint Fluo-3 
staining were not detected by the Track module, owing 
to a low responses to KCl stimulation, and therefore were 
not included in the analysis. Inclusion criteria for data 
analysis were: (i) puncta labeling with Fluo-3, (ii) puncta 
showing a prompt Ca2+ rise and sustained Ca2+ response 
(which was more than 20% increase over resting baseline), 
(iii) puncta returning to fluorescence baseline level. For all 
calcium signals, amplitude, time to peak, peak to baseline 
and overall duration of the response were determined. In 
few control experiments performed to evaluate the source 
of Ca2+ increase, a medium containing 0.1 mM Ca2+ and 
500 μM EGTA was used and no statistically significant 
fluorescence variation and/or typical curve shape was 
detected. 
Neuronal culture and treatments
Hippocampal neurons were prepared from 
embryonic day 17-18 (E17/E18) embryos from timed 
pregnant Wistar rats (Charles River), as we previously 
reported [34]. In detail, the hippocampus was dissected 
out in Hanks’ balanced salt solution buffered with HEPES 
and dissociated via trypsin/EDTA treatment. Cells were 
plated at 1 x 106 cells on 3.5-cm dishes pre-coated with 
poly-D-lysine. After 2 days of culturing in neurobasal 
medium with B-27 supplement and glutamax, cytosine 
arabinofuranoside was added to reduce glial proliferation. 
Half of the medium was changed every 3-4 days and 
mature neuronal cultures were infected at 15 days in vitro, 
as reported in [34].
Assessment of neuronal viability
Cell viability was quantified by counting the number 
of intact nuclei, after lysing in detergent-containing 
solution and by the MTT tetrazolium salt assay, as reported 
in [26, 33, 34]. 
Immunofluorescence
Following treatment, neuronal cultures were washed 
twice with PBS and fixed in 4% (w/v) paraformaldehyde 
for 15 min at room temperature. Cells were permeabilized 
with 0.1% (v/v) Triton X-100/PBS pH 7.4 for 4 min at 
room temperature. Coverslips were saturated with 2% 
BSA and 10% normal goat serum (NGS) for 3h followed 
by incubation overnight at 4 °C in a humidified chamber 
with primary antibodies. Unbound antibody was removed 
by three washes and bound antibody was detected by 
incubation with donkey anti-rabbit Alexa 488 (1:300) 
and donkey anti-mouse rhodamine- conjugated (1:300) 
secondary antibodies (Invitrogen) at room temperature 
for 30 min. Nuclei were stained with nuclear marker 4, 
6-diamidino-2-phenylindole dihydrochloride (DAPI; 
Sigma, St. Louis, MO, U.S.A.) 1:1000 in PBS for 5 min. 
Controls were performed by omitting either the primary 
or the secondary antibody. Images are representative of at 
least three independent experiments.
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Live-fluorescence protocol
Morphological detection of cell-surface NH2htau 
was performed according to procedure aimed to detect 
direct interaction of extracellular-added Aβ 1-42 
peptide to neuronal membrane lipids rafts with several 
modifications [145]. In brief, live neuronal cultures were 
washed twice with chilled PBS 1X , incubated for 10’ with 
1µM FITC-conjugated NH2htau (Biosynthesis, USA) at 
4°C and then labeled for lipid rafts by means of TRITC- 
conjugated cholera toxin subunit B (CT-B), according 
to manual instructions (Vybrant lipid raft labeling kit, 
Molecular Probes). After three washes with chilled PBS 
1X, cells were fixed in 4% (w/v) paraformaldehyde for 
15’ min at 4°C and coverslip slides were then mounted 
in medium containing the nuclear counterstain, DAPI. 
For morphological detection of synaptosomes-surface 
NH2htau, 1µM FITC-conjugated NH2htau was added 5 
min to synaptosomal preparations and after two washes 
the FM4-64 assay(see above) was performed (50µM 
1’+30mM KCl 90sec). Images are representative of at 
least three independent experiments.
Subcellular fractionation and isolation of 
membrane-containing fraction
Biochemical detection of cell-surface NH2htau 
was performed according to procedure aimed to detect 
direct interaction of extracellular-added Aβ 1-42 peptide 
to hippocampal membranes with several modifications 
[146]. In brief, mature hippocampal neurons were exposed 
to NH2htau or its reverse (5µM) at 4°C per 1h and then 
membrane-insoluble BS3 (Thermo Fisher) was used for 
crosslinking molecules on the cell surface, according to 
manual instructions. After that tau-treated and untreated 
control cultures underwent subcellular fractionation to 
obtain cytosol and membrane fractions. Neurons were 
scraped in 5mM EDTA in phosphate-buffered saline (PBS) 
e pelleted by centrifugation for 10’ at 2300 Xg at 4°C. 
Pellets (P1) were resuspended in 100µl of fractionation 
buffer (0.25M sucrose 1mM MgCl2 , 2mM EGTA, 25mM 
HEPES ph 7.4) and lysed by three cycles of freeze-thaw 
in liquid nitrogen. Lysated were then centrifugated at 
100, 000X g for 30’ and the supernatant (cytosol fraction) 
was removed. The membrane-containing pellets (P2) 
were resuspended in 100µl of fractionation buffer and 
equivalent volume of loading dye. Equal amounts of 
proteins were analyzed by Western blotting with our 
12A12 antibody directed against the extreme N-terminal 
26-36 aa of human tau protein. 
Protein cellular lysates preparation
Total proteins were extracted by scraping the cells in 
an SDS-reducing sample buffer or lysis in ice-cold RIPA 
buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton, 
2 mM EDTA, 0, 1% SDS plus proteases inhibitor cocktail 
(Sigma Aldrich, P8340) and phosphatase inhibitor cocktail 
(Sigma Aldrich, P5726/P2850) and centrifuged at 4 °C for 
15 min at 1000 X g. The supernatant was then collected 
and boiled for 5 min. 
Western blot analysis and densitometry
Equal amounts of protein were subjected to 
SDS-PAGE 7.5-15% linear gradient or Bis- Tris gel 
4-12% (NuPage, Invitrogen). After electroblotting 
onto a nitrocellulose membrane (Hybond-C Amersham 
Biosciences, Piscataway, NJ) the filters were blocked in 
TBS containing 10% non-fat dried milk for 1h at room 
temperature or overnight at 4°C. Proteins were visualized 
using appropriate primary antibodies. All primary 
antibodies were diluted in TBS and incubated with the 
nitrocellulose blot overnight at 4°C. Incubation with 
secondary peroxidase coupled anti-mouse, anti-rabbit or 
anti-goat antibodies was performed by using the ECL 
system (Amersham, Arlington Heights, IL, U.S.A.) In 
a few experiments, multiple normalizations of the same 
filter on different loading controls, such as β-actin and 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase), 
were carried. Final figures were assembled by using Adobe 
Photoshop 6 and Adobe Illustrator 10 and quantitative 
analysis of acquired images was performed by using 
ImageJ (http://imagej.nih.gov/ij/).
DLS experiment and data analysis
High-purity tau peptides were suspended in PBS 
solution (10× PBS: 1.3 M NaCl, 0.07 M Na2HPO4 and 
0.03 M NaH2PO4, pH 7.4) at the nominal concentration of 
2.5 mg/ml. Subsequently, the solution was centrifuged for 
10 min at 10 000g and the supernatant filtered to eliminate 
aggregates. DLS measurements were performed by using 
a Zetasizer Nano ZS (Malvern, Herrenberg, Germany) 
equipped with a 633-nm He-Ne laser and operating at an 
angle of 173°. Solvent-resistant micro cuvettes (ZEN0040, 
Malvern, Herrenberg, Germany) have been used for 
experiments with a sample volume of 40 µL. 
Dynamic light-scattering (DLS) 
measures the intensity autocorrelation function 
( ) 22 )()( IItIG τττ += , where τ is the lag time 
and the bracket represents the ensemble average. The 
G2(τ) can be related to the field autocorrelation function 
g1(τ) through the Siegert relation G2(τ) = 1+βg1
2(τ), where 
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β is an instrumental constant equal to 1 in our setup. 
The mathematical form of g1(τ) depends on the physical 
properties of the system investigated. For a monodisperse 
solution of noninteracting particles, a single exponential 
function with decay time τ is obtained. For a polydisperse 
sample, g1 (τ) is no longer a single exponential. In this 
case, the distribution of decay rates on g1(τ) can be taken 











where PI (r)dr is the intensity-weighted radius 
distribution function, describing the distribution of the 
fraction, in the interval dr, of the intensity scattered 







 with η is the water viscosity and k the 
Boltzmann constant [92, 93].The value PI(r) can be 
obtained by means of a regularized Laplace inversion 
of the intensity autocorrelation function. In this case the 
intensity-weighted radius distribution is obtained by a 
direct numerical inversion of the DLS data. The numerical 
inversion is automatically performed by the Malvern 
instrument software. 
The number-weighted radius distribution PN(r) can 
be recovered by taking into account the form factor P(qr) 








The recovery of PN (r) from PI (r) is automatically 
performed by the Malvern software package. Once the PN 
(r) and the PI (r) are known, it is thus easy to determine 







SAXS experiment and data analysis
High-purity tau peptides were dissolved in PBS 
solution (10× PBS: 1.3 M NaCl, 0.07 M Na2HPO4 and 
0.03 M NaH2PO4, pH 7.4). Peptides concentration was 
carefully determined through the Guinier approximation 
and reported in tab. 1. Subsequently, the solution was 
centrifuged for 10 min at 10 000g and the supernatant was 
filtered to eliminate aggregates. SAXS measurements were 
acquired on the BioSAXS beamline (BM-29) at ESRF 
(Grenoble, France), equipped with a 2D detector (Pilatus 
1M, Dectris). The sample to detector distance for normal 
operation is 2.5 m, which allows a momentum transfer 
of s = (4π sin θ/λ) in the range from 0.05 to 5.8 nm−1. 
A volume of 50 μL of solution was placed in a 1.8 mm 
diameter quartz capillary (mounted in vacuum) with a few 
tens of micrometer wall thickness, using an automated 
sample loader. The potential effect of radiation damage 
was evaluated performing a 10 s exposure at constant 
temperature without observing any radiation damage. An 
exposure time of 2 s at each temperature was used to avoid 
possible radiation damage and experimental measures 
were carried out at room temperature. Solvent scattering 
was evaluated- before and after measuring the samples - in 
the same capillary sample holder to allow for background 
scattering subtraction.
Peptides sizes were estimated by their radius of 
gyration RG obtained with two different methods: the 
Guinier approximation and the Debay model. The first 
model states that for very small angles (s < 1/RG) the 








where I(0) is the total scattered intensity at s = 0. 
Given eq. 5, the scattering intensity plotted as ln I(s) 
vs. s2 (Guinier’s Plot) is a linear function for a particle of 
any shape. The radius of gyration of both peptides was 
determined by a linear fit of the Guinier plot. However, 
since the presence of aggregates and oligomers in solution 
can lead to an overestimation of RG, we also used the 
Debye’s approximation according to which, for a Gaussian 
chain, the scattered intensity I(s) of the RG of the chain can 
be expressed by the equation: 
( ) ( )( )21
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 eq. 6
This approximation holds for a larger momentum 
transfer ranges with the respect to the Guinier 
approximation and therefore is less affected by the 
presence of oligomers and aggregates [95]. We 
investigated the peptides flexibility by means of the Kratky 
plot (s2I(s) as a function of s) that is routinely employed to 
qualitatively identify disordered states that are extremely 
frequent in the full length human tau and in almost all 
its fragments exception made for 306VQIVYK311 and 
275VQIINK281 , two hexapeptides with a high propensity to 
form beta-structures [98, 99]. 
Given the highly flexible nature of tau and of 
almost its fragments, an explicit description of the 
structural ensemble visited by both peptides was given 
by means of the EOM software package [95]. Different 
pools of representative backbone models with different 
numerosities were generated for each fragment, namely 
10.000, 50.000 and 100.000. The theoretical scattering 
intensities corresponding to these models were calculated 
by means of the program CRYSOL. These intensities were 
then used by the genetic algorithm GAJOE to select from 
the initial pool an ensemble of conformers providing, on 
the average, the best fit of the experimental SAXS data. 
The following GAJOE parameters were set: number of 
generations, 1.000; number of ensembles, 50; number 
of curves per ensemble, 20; number of mutations per 
ensemble, 10; number of crossings per generation, 20. A 




Experiments were carried out in triplicates and 
repeated at least three times. Data were expressed as 
means ± S.D. (n = 4). Statistically significant differences 
were calculated by unpaired two-tailed t-Student’s test 
and one-way ANOVA followed by Bonferroni post-hoc 
test (*p < 0, 05; **p <0, 01; ***p <0, 0001) as indicated 
in the figure legends. Data from Western blot analysis and 
immunofluorescence studies were representative of at least 
three separate experiments.
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